Method of prostate cancer treatment using herbal compositions


FIELD: medicine.

SUBSTANCE: group of invention concerns medicine, namely to oncology and can be used in prostate cancer treatment. The methods of the invention imply administration of a composition containing therapeutically effective quantities of supercritical extracts of rosemary, curcuma, marjoram and ginger, as well as therapeutically effective quantities of water-alcoholic extracts of holy basil, ginger, curcuma, Scutellaria baicalensis, rosemary, green tea, Polygonum cuspidatum, Coptis chinensis Franchet and barberries.

EFFECT: inhibition of prostate cancer cell growth due to the effect of COX-2 composition without any significant side-effects.

36 cl, 1 tbl, 5 dwg, 4 ex

 

The LEVEL of TECHNOLOGY

1. The technical field to which the invention relates.

The present invention relates to new ways of treating prostate cancer, comprising the introduction of compositions containing therapeutically effective amounts of supercritical extracts of rosemary, turmeric, oregano and ginger; and therapeutically effective amounts of hydroalcoholic extracts of the Basilica of the sacred (Ocimum. sanctum), ginger, turmeric, Scutellaria baicalensis, rosemary, green tea, Polygonum cuspidatum, coptis Chinese and barberry.

2. The level of technology

Cancer of the prostate. Prostate cancer is the third on the prevalence of the cause of death from malignant tumors in men of all ages and the most common cause of death from malignant tumors in men older than 75 years. Prostate cancer is rarely find in men younger than 40 years. Men with a higher risk include blacks over the age of 60, farmers, tire, artists, and men exposed to cadmium. The lowest frequency occurs in Japanese men and vegetarians. The cause of prostate cancer is unknown, although some studies have shown an Association with high consumption of fat in the diet or a high level of testosterone.

Prostate cancer is the Wallpaper of serious and often life-threatening condition. Prostate cancer, which is characterized by the growth of rapidly proliferating cells, continues to be the subject of studies conducted around the world, aimed at the identification of therapeutic agents that are effective for its treatment. Effective therapeutic agent prolong the survival of the patient, inhibit the growth of rapidly proliferating cells associated with a disease, or affect the regression of the disease. Research in this area mainly focused on the identification of funds therapeutically effective in humans and other mammals.

Prostate cancer, like all solid tumors, is characterized by metastatic invasion of the tumor, affecting other vital functions, which causes the death of the patient. Approximately 10% of patients first diagnosed at the stage of the disease with metastases. Ultimately 30-40% of patients with this cancer develop metastatic disease. After the occurrence of metastases cancer progresses quickly, without interruption effective treatment. Prostate cancer is classified based on its aggressiveness and differences in terms of the surrounding tissue of the prostate. There are several different ways to classify tumors; one of the most famous is the Whitmore-Jewett, in which the tumors are subjected to the following classification:

A: the tumor cannot be felt during physical examination and usually detected incidentally after prostate surgery performed for other reasons.

In: tumor confined to the prostate gland and is usually determined by medical examination or PSA testing.

With: extension of tumor beyond the capsule of the prostate without spread to the lymph nodes.

D: a malignant tumor spreads to regional lymph nodes or other parts of the body such as the bones or lungs.

Using test prostatespecific antigen ("PSA"), the majority of prostate cancers currently find before the appearance of symptoms. The symptoms listed below, are possible indicators of prostate cancer: variations of the pressure of urine, dripping urine, retention of urine, pain during urination, pain during ejaculation, back pain, pain during bowel movement, excessive urination at night, pain or brittle bones, hematuria, abdominal pain, anemia, weight loss and lethargy.

Appropriate treatment for prostate cancer is often controversial. Treatment options vary depending on the stage of the tumor. In the early stages for the eradication of tumors can be used to remove the prostate gland and radiationtherapy. Metastatic prostate cancer can be treated with hormones, reduced levels of testosterone drugs or removal of the testicles, or by chemotherapy.

Surgical removal of the prostate gland has several possible complications, including impotence and incontinence. Removal of the testicles alters hormone production and can be recommended when metastasise tumors and has possible complications, including loss of production of testosterone, which leads to problems with sexual function, osteoporosis and loss of muscle mass. Therapy irradiation has possible complications, including loss of appetite, fatigue, skin reactions such as redness and irritation, burning or damage of the rectum, diarrhea, cystitis and blood in the urine. The use of hormones, which is mainly used to alleviate the symptoms without treating prostate cancer, has possible complications, including nausea and vomiting, hot flashes, anemia, lethargy, osteoporosis, decreased libido, liver problems, diarrhea, breast enlargement and erectile dysfunction together with the apparent lack of treatment of the disease as such. Chemotherapy using drugs such as mitoxantrone, prednisone, paclitaxel, docetaxel, estramustine and adriamycin has the potential Oslon the tion, which are numerous and specific to this drug for chemotherapy.

Suffering from prostate cancer patients often experience significant lifestyle changes, including impaired libido or impaired sexual function on a temporary or permanent basis; impotence; intensive monitoring of disease progression; stress or disease, and urinary incontinence.

Thus, there is a continuing need for alternative ways to treat prostate cancer and better ways to treat prostate cancer.

Cyclo-oxygenase inhibitors. The cyclooxygenase is an enzyme - protein complex with different types of biochemical actions. There are at least three primary isoenzyme MOR, MOR-1 AND MOR-2 MOR-3. MOR-1 is a constitutive enzyme that is constantly produced with a moderate constant level. It plays an important role, for example, when the protection in the gastrointestinal tract, the kidneys and the aggregation of blood platelets. Products SOH-2 is unstable; it varies depending on signals from various biological catalysts.

For example, in the case of inflammation and pain of arthritis, SOH-2 responds to tissue damage by oxidation of arachidonic acid, with the receipt of prostaglandins, which, in the howling of all, produce inflammation. MOR-3 was identified relatively recently (Chandrasekharan, et al., PNAS U.S.A., 99 (21): 13926-31 (2002)). People mRNA MOR-3 is expressed most abundantly in the brain and cardiac tissues. Activity MOR-3 is selectively inhibited by analgesics/antipyretics. It was assumed that the inhibition of MOR-3 may represent a mechanism by which these medicines reduce pain and possibly fever.

Prostaglandins play a major role in the process of inflammation, and inhibition of production of prostaglandins, especially the production of PGG2, PGH2 and PGE2, is a common target opening anti-inflammatory drugs. However, conventional non-steroidal anti-inflammatory drugs ("NSAID"), which is active in terms induced by prostaglandins pain and swelling associated with inflammation, is also active in influencing regulated by prostaglandins processes not associated with inflammation.

It was found that NSAIDs prevent the production of prostaglandins by inhibition of enzymes of human rights in the way arachidonic acid/prostaglandin, enzyme induction of cyclooxygenase. Traditional non-steroidal anti-inflammatory drugs, such as aspirin, acting through the inhibition of MOR-1 and MOR-2. Thus, nonspecific NAID can have a damaging effect on the gastro-intestinal tract, kidneys and liver; blocking MOR-1 can make the lining of the stomach more vulnerable, and decreased production of thromboxane thins the blood, which leads to greater likelihood of gastrointestinal bleeding and can cause inadequate regulation of cellular immune function and the secretion of various cytokines.

The use of high doses of the most common NSAID can produce severe side effects, including life-threatening ulcers that limit their therapeutic potential.

SOH-2 are associated with inflammation and provides a viable target of inhibition which more effectively reduces inflammation and produces less intense side effects. Thus, the researchers had the motivation for the development of selective inhibitors of MOR-2 to reduce inflammation and relieve the pain without damage to the gastrointestinal tract caused by inhibition of MOR-1. In addition, modern scientific understanding in this field indicates that the inhibition of MOR-2 may serve an important function to prevent the normal growth of cells in the intestine, pancreas, breast tissue, and other organ systems.

Some compounds that selectively inhibit cyclooxygenase-2, is described in U.S. patent№5380738, 5344991, 5383790, 5434178, 5474995, 5510368 and the documents WO 96/06840, WO 96/03388, WO 96/03387, WO 96/2405, WO 95/15316, WO 94/15932, WO 94/27980, WO 95/00501, WO 94/13635, WO 94/20480 and WO 94/26731.

Drugs such as valdecoxib, celecoxib and rofecoksib supposed selectively inhibit SOH-2 with minimal impact on MOR-1. However, despite the emphasis on inhibition of MOR-2, even these medicines, as it turns out, have serious long-term side effects such as the destruction of the digestive protective mucus and prevent normal healing processes. Thus, there is a continuing need for more specific and nonspecific inhibitors SOH-2, which avoids the side effects associated with inhibition of MOR-1.

Natural inhibitors SOH-2. Some herbs, has been found to inhibit the enzyme SOH-2. For example, Holy Basil, has been found to possess significant anti-inflammatory properties and is able to block ziklooksigenazny and lipoxygenase metabolic pathways of arachidonate. Ursolic acid and oleanolic acid, two of the detected phytonutrient Basilica, has been found to have significant activity against inhibition of MOR-2.

Similarly, shogaol and gingerol, pungent components of ginger was found to inhibit cyclooxygenase.

Eugenol, the other active component of some medicinal herbs, as well as found, is an inhibitor of 5-lipoxygenase and has powerful anti-inflammatory and/or anti-rheumatic properties.

Scutellaria baicalensis, as it was found, inhibits the enzyme SOH-2. According to the database USDA green tea contains six components that have inhibitory activity against cyclooxygenase. According to the database Napralert green tea contains fifty-one component having anti-inflammatory activity. The polyphenols in green tea, has been found to cause significant reduction in MOR-2. (+)-catechin, derived flavan-3-ol, also present in green tea, as reported, is also an inhibitor of MOR-1 and MOR-2. In addition, salicylic acid, another component of green tea, as well as discovered, is an inhibitor SOH-2.

Berberine, found in barberry and coptica Chinese, as well as discovered that inhibits SOH-2 without inhibiting the activity of MOR-1.

In U.S. patent No. 6387416 applicants describe the composition of the invention and their use to reduce inflammation. The contents of U.S. patent No. 6387416 fully included here as a reference. Suddenly, as further discussed below, it was determined that the composition of the invention can also be used to treat prostate cancer.

Inhibitors SOH-2 for the treatment of cancer. Was Postol is granted, the inhibitors SOH-2 can be used for cancer treatment. Only a few patents actually describe inhibitors SOH-2 for the treatment of any malignant tumors. In U.S. patent 5466823 issued Talley, et al., (pyrazole-1-yl)benzosulfimide described as inhibitors of cyclooxygenase-2 and for use in the treatment of inflammation, arthritis and pain, and as compounds that can be used for the prevention of colon cancer. However, their use for the actual treatment of colon cancer or for the treatment or prevention of other alterations not described.

In U.S. patent No. 6469040 issued by Seibert et al., the described method of application-specific, described class derived inhibitors of cyclooxygenase-2 in the prevention and treatment of the subject of epithelial neoplasia.

In U.S. patent No. 6534540 issued Kindness et al., the described combination of proprietary inhibitor of HMG-CoA reductase lovastatin and proprietary inhibitor SOH-2 rofecoxib for the treatment of malignant tumors, especially prostate cancer, and a method of treatment of malignant tumors, especially prostate cancer, this combination.

Based on the limited amount of research in this area, describes the use of inhibitors SOH-2 for the treatment of any cancer, and the need for effective methods for the treatment of RA is and prostate cancer in particular, it is clear that there is great and urgent need for new inhibitors SOH-2 for the treatment of prostate cancer. This need is met by the methods and compositions according to the invention, which treat neoplasia of the prostate without significant side effects.

The INVENTION

The present invention relates to a method of treatment of the subject has neoplasia prostate cancer, including the stage of introducing an effective amount of the composition specified subject for treatment or prevention of a specified neoplasia of the prostate gland, and the specified composition comprises therapeutically effective amounts of supercritical extracts of rosemary, turmeric, oregano and ginger; and therapeutically effective amounts of hydroalcoholic extracts of the Basilica of the sacred, ginger, turmeric, Scutellaria baicalensis, rosemary, green tea, Polygonum cuspidatum, coptis Chinese and barberry, when providing that specified neoplasia of the prostate is not intraepithelial neoplasia of the prostate gland.

In addition, the present invention relates to a method of treatment of a subject at least one malignant tumors of the prostate, comprising the stage of introducing an effective amount of the composition specified subject or for the treatment profile is Tiki specified tumor, moreover, this composition contains therapeutically effective amounts of supercritical extracts of rosemary, turmeric, oregano and ginger; and therapeutically effective amounts of hydroalcoholic extracts of the Basilica of the sacred, ginger, turmeric, Scutellaria baicalensis, rosemary, green tea, Polygonum cuspidatum, coptis Chinese and barberry.

In addition, the present invention relates to a method of treatment of a patient side effects associated with neoplasia of the prostate, comprising the stage of introducing an effective amount of the composition specified subject for treatment of the above side effects, and this composition contains therapeutically effective amounts of supercritical extracts of rosemary, turmeric, oregano and ginger; and therapeutically effective amounts of hydroalcoholic extracts of the Basilica of the sacred, ginger, turmeric, Scutellaria baicalensis, rosemary, green tea, Polygonum cuspidatum, coptis Chinese and barberry, where these side effects selected from the group consisting of impaired libido or impaired sexual function in a temporary or permanent basis, impotence, long-term monitoring of the progress of the disease, stress-related disease, and urinary incontinence.

BRIEF DESCRIPTION of DRAWINGS

Figure 1 is a graph motoryacht inhibition of MOR-2, carried out by the compositions according to the invention.

Figure 2 is a photograph which illustrates a Western blot of the expression of MOR in LNCaP cells after treatment with compositions according to the invention.

Figure 3 is a graph which illustrates the effects on growth inhibition of LNCaP cells compositions according to the invention.

Figure 4 is a photograph that illustrates the Western blot fragments of PARP cleavage in treatment of LNCaP cells with the compositions according to the invention.

Figure 5 is a graph which represents the activity of caspase-3 in LNCaP cells after treatment with compositions according to the invention.

DETAILED description of the INVENTION

Definition

Used herein, the term "therapeutically effective amount" refers to that amount of the extract, which will contribute to the ability of the composition to cure cancer.

Used herein, the term "treatment" refers to partial or complete inhibition of growth, proliferation or metastasis of a neoplasm of the prostate, as well as partial or complete destruction of cancer cells. The term "treatment" includes the reduction or elimination of neoplasia of the prostate and also a reduction in the frequency of occurrence of the disease.

Used herein, the term "prevention" refers to prophylact the ke early neoplasia of the prostate, or to the prevention stage neoplasia of the prostate gland that are not detected clinically in subjects at risk. This also implies that this definition covers the prevention of initiation of malignant cells and stops or reverses the progression of pre-malignant cells into malignant. "Prevention" also includes the prevention of the growth or spread of a neoplasm of the prostate. This includes prophylactic treatment of patients at risk of developing neoplasia of the prostate gland.

Used herein, the term "supercritical gas or supercritical fluid" refers to a gas that is heated to a critical temperature point above which the gas will maintain its gaseous state and will not turn into a liquid regardless of the pressure. Gas heated to a temperature above the critical point, will be very tight under pressure, so that its characteristics resemble those for the fluid, but it will become liquid. Carbon dioxide is typically used in applications requiring a supercritical fluid. General properties of supercritical fluids and General application of supercritical fluids extraction processes are described, for example, in Taylor, Supercritical Fluid Extraction, Wiley, 1996; McHugh and Krukonis, Supercritical Fluid Extraction: Principles and Practice, 2nd ed., Butterworth-Heineman, 1994; Williams and Clifford, Supercritical Fluid Methods and Protocols, Humana Press, 2000, the contents of which are incorporated here by reference.

Used herein, the term "supercritical extraction" refers to the way in which hydrophobic substances can be extracted from the samples using supercritical fluid. The solvent power of the supercritical fluid increases as the pressure and temperature are increased above their critical points, which produces an effective solvent for separation of hydrophobic molecules.

Used herein, the term "hydroalcoholic extraction" refers to the way in which hydrophilic compounds can be extracted from the sample using a solution of alcohol and water, followed by evaporation of the solution, with products extract, consisting of dissolved solids.

Used herein, the term "neoplasia" refers broadly to a neoplastic, pre-malignant or proliferative disease, specifically including benign, pre-malignant and malignant neoplasia in subjects with the presence or absence of previous history of neoplastic, predzakatnogo and proliferative diseases. The term "neoplasia" includes neoplasia, which produces prostaglandins or expresses cyclooxygenase, including welcome acetone and malignant tumors, growths and polyps.

Used herein, the term "neoplasia of the prostate" refers in a broad sense to epithelial cancers, epithelioma, carcinomas, sarcomas or other malignant tumors or neoplasms of glandular origin in the prostate gland.

Used herein, the term "subject" refers to any entity, person or mammal, suffering from a neoplasia of the prostate gland, it is preferable to subject-person. The methods of the invention, the subject is any subject, human or animal, preferably the subject is a person who is at risk of developing neoplasia prostate cancer derived from epithelial cells. The subject may include at risk due to exposure to carcinogenic agents, being genetically predisposed to having neoplasia of the prostate, and the like.

Used herein, the term "inhibitor of cyclooxygenase-2" or "inhibitor " -2" refers to a compound or composition capable of inhibiting cyclooxygenase without unwanted inhibition of cyclooxygenase-1.

TREATMENTS for PROSTATE CANCER

Although the frequency of occurrence of localized, latent prostate cancer is uniform around the world, the incidence of metastatic RA is and prostate cancer is much higher in Western countries than in Eastern countries.

This significant discrepancy indicates participation in the development of metastatic prostate cancer environmental factors, and it stimulated some epidemiological studies that indicate a link between a diet high in fat and risk of metastatic prostate cancer. And arachidonic acid and its precursor linoleic acid are present in significant amounts in animal fats and various vegetable oils. Physiologically these fatty acids are integral components of cell membranes and also function as a substrate for the production of an important group effective at signaling lipids, called eicosanoids. Eicosanoids, known to be involved in the initiation of inflammatory responses, leading to a feverish state, regulation of blood pressure, blood clotting, control of reproductive and growth processes in tissues, and regulation of the cycles of sleep/wakefulness. In addition, these powerful mediators and enzymes that they produce, cyclooxygenase (SOH) and lipoxygenase (LO), involved in the development of tumor progression and metastasis.

Three major isoforms of cyclooxygenase are MOR-1 AND MOR-2 MOR-3, and the enzymes responsible for the production of a group of eicosanoids, protag is antinov. Isoform MOR-1 has many important control functions in the cell and therefore is produced in all cells of the body. However, MOR-2 is usually absent in the cell until is induced by specific stimuli. Consequently, it is not surprising that MOR-2 is involved in the development of many disease States including cancer. Detected the presence of increased levels of MOR-2 in various types of cancer, including cancers of the lung, breast, pancreas, head and neck, skin, glioblastoma and prostate cancer. As discussed above, MOR-3 discovered relatively recently.

In relation to prostate cancer has been demonstrated that elevated levels of MOR-2 are present in some tumor samples, and had elevated levels of the enzyme SOH-2 in the progression of the disease. Activity SOH-2 and the resulting production of prostaglandins are also involved in induced tumor angiogenesis, which, as expected, is mediated by some inhibitors SOH-2. In addition, the inventors expect that some inhibitors SOH-2 lead to the re-initiation pathways of apoptosis, overcoming protivoponosnye factors secreted by tumor cells, and providing cell death.

Ancient natural remedy based on the use of white willow bark (Salix alba), not what vtorogo pain relief, led to the discovery of aspirin and, eventually, to the elucidation of the mechanisms of its action as inhibitors of SOKH. Based on this medicinal prototype and other traditional Western medical practices, many researchers turned to the study of various natural plant extracts and natural products for the discovery of non-specific inhibitors SOKH and specific inhibitors SOH-2. Some herbal extracts and natural products attracted great interest among researchers, include curcumin, ginger, Basil, resveratrol, Chinese vine (Tripterygium Wilfordii) and berberine from Berberis and Coptic Chinese.

Applicants have developed a mixture consisting of herbal extracts, this formula has a MOR-2-inhibitory activity. Connections developed by the applicants, the unique composition of herbs, their combination and value, synergy and activity of herbs, as well as in connection with obtaining them by supercritical extraction CO2. Unlike traditional methods of extraction, based on the dissolution of supercritical extraction of CO2allows you to get natural products contained in herbs, without loss of chemicals in the production process.

Unexpectedly, in addition to anti-inflammatory action, is described in U.S. patent No. 6387416, the inventors have found that the use of compositions and methods according to the invention causes inhibition of MOR-2 and antineoplastics activity in cell lines of prostate cancer. The inventors have also expect that the methods of the invention induce apoptosis and inhibit cell growth of cancer cells, in which deactivated the way of apoptosis.

The method according to the invention based on the discovery that the combination of certain herbs, properly extracted and blended in certain proportions, can be used in the treatment of neoplasia of the prostate. Thus, the present method according to the invention relates to a method of treating neoplasia of the prostate in a subject, comprising the stage of introducing an effective amount of the composition specified subject for treatment or prevention of a specified neoplasia of the prostate where the specified composition comprises therapeutically effective amounts of supercritical extracts of rosemary, turmeric, oregano and ginger; and therapeutically effective amounts of hydroalcoholic extracts of the Basilica of the sacred, ginger, turmeric, Scutellaria baicalensis, rosemary, green tea, Polygonum cuspidatum, coptis Chinese and barberry, while ensuring that the specified neoplasia of the prostate is not intraepithelial neoplasia of the prostate gland.

In one aspect the aspect of the specified composition is administered orally.

In another preferred embodiment, the input oral composition is applied is as one or more capsules, one or more tablets or one or more pills.

In another aspect, the composition contains:

(A) from about 4.5% to 7.5% and more preferably from about 5.5% to about 6.5% by weight of the hydroalcoholic extract of ginger;

(B) from about 5.5% to 8.5% and more preferably from about 6% to 8% by weight of the supercritical extract of ginger;

(C) from about 1.0% to 1.5% and more preferably from about 1.2% to 1.4% by weight of the supercritical extract of turmeric;

(D) from about 10.0% to 16.0%, and more preferably about 11.5% to 14.5% by weight of the supercritical extract of rosemary;

(E) from about 4.0 percent to 6.0 percent, and more preferably approximately from 4.5% to 5.5% by weight of the supercritical extract of oregano;

(F) from about 10.0% to 16.0%, and more preferably about 11.5% to 14.5% by weight of the hydroalcoholic extract of turmeric;

(G) from about 5.5% to 8.0%, more preferably from about 6.0% to 7.0 percent by weight of the hydroalcoholic extract of rosemary;

(H) from about 10.0% to 16.0%, and more preferably about 11.5% to 14.5% by weight of the hydroalcoholic extract of the Basilica of the sacred;

(I) from about 10.0% to 16.0%, and more preferably about 11.5% to 14.5% by weight of the hydroalcoholic extract of green tea;

(J) from about 8.0% to 12.0% and more preferably approximately from 9.0% to 11.0% by weight of the hydroalcoholic extract of Polygonum cuspidatum;

(K) from about 4.0 percent to 6.0 percent, and more preferably approximately from 4.5% to 5.5% by weight of the hydroalcoholic extract of coptis Chinese;

(L) from about 4.0 percent to 6.0 percent, and more preferably approximately from 4.5% to 5.5% by weight of the hydroalcoholic extract of barberry;

and

(M) from about 2.0% to 3.0% and more preferably approximately from 2.25% to 2.75% by weight of the hydroalcoholic extract of Scutellaria baicalensis.

The hydroalcoholic extract of ginger used in the present invention, preferably prepared as follows. The rhizome of ginger, shredded preferably cryogenic to protect heat sensitive components, is subjected to supercritical extraction, preferably carbon dioxide, to obtain: (i) extract in the form of oil, here called "supercritical extract, ginger contains volatile lipophilic components, and (ii) do not contain oil residue. Does not contain oil residue then extracted in a mixture of water/alcohol, preferably water/ethanol containing 60 to 80 parts of alcohol and 40-20 parts of water. A solution of the alcohol/water is then evaporated, leaving a powdery residue of the extract, called here "the hydroalcoholic extract of ginger.

In a preferred embodiment, the mass ratio of the supercritical extract of ginger to the hydroalcoholic extract of ginger should be approximately from 0.9: 1.4:1.

Supercritical extracts of ginger, rosemary, turmeric and oregano used in the compositions according to the invention, can be obtained in accordance with known methods, supercritical extraction, as described, for example, in .Stahl, K.W.Quirin, D.Gerard, Dense Gases for Extraction and Refining, Springer Verlag 4 1988, incorporated herein by reference.

Hydroalcoholic extracts of rosemary, turmeric, Basilica of the sacred, Polygonum cuspidatum, coptis Chinese, barberry and Scutellaria baicalensis used in the compositions according to the invention, can be obtained in accordance with generally accepted ways hydroalcoholic extraction. For example, the hydroalcoholic extracts can be obtained by extracting portions of the plants in a mixture of water/alcohol, preferably water/ethanol containing 60 to 80 parts of alcohol and 40-20 parts of water, and then by evaporation of a solution of the alcohol/water, leaving powdery residue of the extract, called here "the hydroalcoholic extract".

In another aspect, the mass ratio of the hydroalcoholic extract of turmeric to the supercritical extract of turmeric ranges from about 8:1 to 12:1.

In another aspect, the mass ratio of the supercritical extract of rosemary to the hydroalcoholic extract of rosemary is about 1.6:1 to 2.4:1.

In another aspect of the hydroalcoholic extract of ginger contains approximately from 2.4% to 3.6%, more predpochtite the flax from about 2.7% to 3.3% and most preferably about 3.0 percent burning substances, mass.

In another aspect of the supercritical extract of ginger contains from about 24% to 36%, more preferably from about 27% to 33%, and most preferably about 30% pungent substances, by weight; and from about 6.4% to about 9.6%, more preferably from about 7.2% to 8.8 percent, and most preferably about 8% zingiberene, mass.

In another aspect of the supercritical extract of turmeric contains from about 36% to 54%, more preferably from about 40.5 percent to 49.5%, and most preferably about 45% of turmerone, mass.

In another aspect of supercritical rosemary extract contains approximately 18.4% to 27.6%, more preferably about from 20.7% to 25.3%, and most preferably about 23% total phenolic antioxidants, mass.

In another aspect of the supercritical extract of oregano contains from about 0.64% to 0.96%, and more preferably from about 0.72% up to 0.88%, and most preferably about 0.8% total phenolic antioxidants, mass.

In another aspect of the hydroalcoholic extract of turmeric contains from about 5.6% to 8.4%, and more preferably from about 6.3% to 7.7 percent, and most preferably about 7% curcumin, mass.

In another aspect of the hydroalcoholic extract of rosemary contains approximately 18.4% to 27.6%, more preferably about from 20.7% to 25.3%, and most preferably about 23% to about what their phenolic antioxidants, mass.

In another implementation of the hydroalcoholic extract of the Basilica of the sacred contains approximately from 1.6% to 2.4%, more preferably from about 1.8% to about 2.2%, and most preferably about 2% of ursolic acid, by mass.

In another aspect of the hydroalcoholic extract of green tea contains approximately 36% to 54%, more preferably from about 40.5 percent to 49.5%, and most preferably about 45% polyphenols, mass.

In another aspect of the hydroalcoholic extract of Polygonum cuspidatum contains from about 6.4% to about 9.6%, more preferably from about 7.2% to 8.8 percent, and most preferably about 8% resveratrol, mass.

In another implementation of the hydroalcoholic extract of coptis Chinese contains from about 4.8% to about 7.2%, more preferably from about 5.4% to 6.6 percent, and most preferably about 6% berberine, mass.

In another aspect of the hydroalcoholic extract of barberry contains from about 4.8% to about 7.2%, more preferably from about 5.4% to 6.6 percent, and most preferably about 6% berberine, mass.

In an alternative aspect, this composition contains:

(A) from about 4.5% to 7.5 percent by weight of the hydroalcoholic extract of ginger, where the extract contains about 2.4% to about 3.6% by weight of pungent substances;

(B) from about 5.5% to about 8.5 percent by weight of the supercritical extract of ginger, where the extract contains primerno 24% to 36% by weight of pungent substances, and from about 6.4% to about 9.6% zingiberene, by weight;

(C) about 1.0% to 1.5% by weight of the supercritical extract of turmeric, where the extract contains from about 36% to 54% of turmerone, by weight;

(D) from about 10.0% to 16.0% of the weight of the supercritical extract of rosemary, where the extract contains from about 18.4% to 27.6% of the total phenolic antioxidants by weight;

(E) from about 4.0 percent to 6.0% by weight of the supercritical extract of oregano, where the extract contains from about 0.64% to 0.96% for total phenolic antioxidants by weight;

(F) from about 10.0% to 16.0% of by weight of the hydroalcoholic extract of turmeric, where the extract contains from about 5.6% to 8.4% of curcumin, by weight;

(G) from about 5.5% to 8.0 per cent by weight of the hydroalcoholic extract of rosemary, where the extract contains from about 18.4% to 27.6% of the total phenolic antioxidants by weight;

(H) from about 10.0% to 16.0% of by weight of the hydroalcoholic extract of the Basilica of the sacred, where the extract contains approximately from 1.6% to 2.4% of ursolic acid, by mass;

(I) from about 10.0% to 16.0% of by weight of the hydroalcoholic extract of green tea, where the extract contains from about 36% to 54% polyphenols by weight;

(J) from about 8.0% to 12.0% by weight of the hydroalcoholic extract of Polygonum cuspidatum, where the extract contains from about 6.4% to about 9.6% of resveratrol, by weight;

(K) from about 4.0 percent to 6.0% by weight of the hydroalcoholic extract of coptis key is isogo, where the extract contains from about 4.8% to about 7.2% of berberine, by weight;

(L) from about 4.0 percent to 6.0% by weight of the hydroalcoholic extract of barberry, where the extract contains from about 4.8% to about 7.2% of berberine, by weight; and

(M) from about 2.0% to 3.0 percent by weight of the hydroalcoholic extract of Scutellaria baicalensis;

and where the specified composition additionally contains:

(i) supercritical extract of ginger and the hydroalcoholic extract of ginger with a weight ratio of from about 0.9 to 1.4 parts supercritical extract to 1 part postsurgical;

(ii) the hydroalcoholic extract of turmeric and supercritical extract of turmeric powder with a weight ratio of from about 8 to 12 parts of a hydroalcoholic extract per 1 part of supercritical extract; and

(iii) supercritical rosemary extract and hydroalcoholic extract of rosemary with weight ratio of from about 1.6 to 2.4 parts supercritical extract per 1 part of the hydroalcoholic extract.

In a preferred implementation, the composition is administered in a daily dose of at least 700 mg

In another aspect the composition is administered for at least 4 weeks, with daily admission.

In an additional aspect of the present invention it relates to a method for treating at least one malignant tumors of the prostate, comprising the stage of introduction efficiency is the amount of aqueous composition a specified subject for the treatment of the said tumor, this composition comprises therapeutically effective amounts of supercritical extracts of rosemary, turmeric, oregano and ginger;

and therapeutically effective amounts of hydroalcoholic extracts of the Basilica of the sacred, ginger, turmeric, Scutellaria baicalensis, rosemary, green tea, Polygonum cuspidatum, coptis Chinese and barberry.

In an additional embodiment of the present invention, at least one tumor detected during surgery of the prostate specified subject, and this tumor is not detected by the doctor during the physical exam of the specified entity.

In addition, the present invention relates, at least one malignant tumor limited to the prostate specified subject and detected by the doctor during a medical examination of a given entity.

An additional aspect of the present invention includes a malignant tumor related at least to one of a malignant tumor, which extends beyond the capsule of the prostate specified subject, but not in the lymph nodes of the specified entity.

Further additional aspect of the present invention refers to a malignant tumor, related to the specified at least one malignant tumor, which is eastserve in regional lymph nodes or other parts of the body of the specified entity.

A preferred aspect of the present invention relates to a method for treating side effects associated with the presence of the subject has neoplasia prostate cancer, including the stage of introduction of a specified subject an effective amount of a composition for the treatment of these side effects, and this composition contains therapeutically effective amounts of supercritical extracts of rosemary, turmeric, oregano and ginger; and therapeutically effective amounts of hydroalcoholic extracts of the Basilica of the sacred, ginger, turmeric, Scutellaria baicalensis, rosemary, green tea, Polygonum cuspidatum, coptis Chinese and barberry, where these side effects selected from the group consisting of impaired libido or impaired sexual function in a temporary or permanent basis, impotence, long-term monitoring of disease progression, stress due to disease and urinary incontinence.

Further preferred variant implementation refers to the way in which a subject to treatment side effects include impaired sexual function.

In an alternative aspect, the composition comprises an additional agent selected from antineoplastics funds, funds-growth inhibitors and nutrients.

There are a large number of antineoplastics what x means, available for commercial use, in clinical trials and pre-clinical development, which are not necessarily selected for the treatment of neoplasia of the prostate by combination drug chemotherapy. Such antineoplastics tools fall into several major categories: tools-antimetabolites, tools, types of antibiotics, alkylating tools, hormonal drugs, immunological assets, type of interferon, matrix metalloprotease, analogues of superoxide dismutase or inhibitors of αVβ3. Thus, in the preferred implementation of the specified antineoplastics means selected from the group consisting of medium-antimetabolites, tools, types of antibiotics, alkylating funds, hormone preparations, immunological equipment, type of interferon, the matrix metalloprotease, analogues of superoxide dismutase inhibitors or αVβ3.

First class antineoplastics tools that can be used in combination with a composition according to the invention, consists of antineoplastics means a type of antimetabolite. Suitable antineoplastics tools-antimetabolites can be selected from the group consisting of 5-FU-fibrinogen, centifolias acid, aminothiadiazole, brequinar sodium, carmofur, CGP-30694 (Ciba-Geigy), cyclopentylmethyl is, tsitarabina phosphate-stearate, conjugates of cytarabine, DATHF (Lilly), DDFC (Merrel Dow), deazaguanine, dideoxycytidine, deocsa, DMDC (Yoshitomi), doxifluridine, EHNA (Wellcome), EX-015 (Merck & Co.), fazarabine, floxuridine, fludarabine phosphate, 5-fluorouracil, N-(2'-furandi)-5-fluorouracil, FO-152 (Daiichi Seiyaku), isopropylpyrazine, LY-188011 (Lilly), LY-264618 (Lilly), metabasepath, methotrexate, MZPES (Wellcome), nonspermicidal, NSC-127716 (NCI), NSC-264880 (NCI), NSC-39661 (NCI), NSC-612567 (NCI), PALA (Warner-Lambert), pentostatin, piritrexim, plicamycin, PL-AC (Asahi Chemical), TAS-788 (Takeda), Tg, tesofensine, TIF (Erbamont), trimetrexate, tyrosine kinase inhibitors, inhibitors tyrosinemia protein kinase, UFT (Taiho), andritsaina.

A second class antineoplastics tools that can be used in combination with a composition according to the invention, consists of antineoplastics funds alkylating type. Suitable antineoplastics means alkylating type can be selected from the group consisting of 254-S (Shionogi), analogues of aldophosphamide, altretamina, anxiron, BBR-2207 (Boehringer Mannheim), astroballe, budotitane, SA-102 (Wakunaga), carboplatin, carmustine, Chinoin-139, Chinoin-153, hlorambuzila, cisplatin, cyclophosphamide, CL-286558 (American Cyanamid), CY-233 (Sanofi), cisplatina, D-19-384 (Degussa), DACHP(Myr)2 (Sumimoto), diphenylpyraline, cytostatica diplotene derived distamycin DWA-2114R (Erba Chugai), E (ITI), elastin, FCE-24517 (Erbamont), estramustine hospitalaria, fotemustine, G-6-M (Unimed), GYKI-17230 (Chinoin), gasulla, ifosfamide, iproplatin, lomustina, mafosfamide, mitolactol, NK-121 (Nippon Kayaku), NSC-264395 (NCI), NSC-342215 (NCI), oxaliplatin, PCNU (decision Upjohn), prednimustine, push to talk-119 (Proter), ranimustine, semustine, SK&F-101772 (SmithKline), SN-22 (Yakult Honsha), spiramycin, TA 077 (Tanabe Seiyaku), tauromachine, temosolomida, taraxerone, tetrapedia and timelabel.

The third class antineoplastics tools that can be used in combination with a composition according to the invention, consists of antineoplastics funds type of antibiotics. Suitable antineoplastics funds type of antibiotic may be selected from the group consisting of 4181-A (Taiho), aclarubicin, actinomycin D, actinoplanes, ADR-456 (Erbamont), derived aerolysin, AN-201-II (Ajinomoto), AN-3 (Ajinomoto), anisomycin (Nippon Soda), anthracycline, sinomenine, boukabara, BL-6859, Bristol-Myers), BMY-25067, Bristol-Myers), BMY-25551, Bristol-Myers), BMY-26605 (Bristol-Myers), BMY-27557 (Bristol-Myers), BMY-28438 (Bristol-Myers), bleomycin sulfate, zorubicin.

Fourth grade antineoplastics tools that can be used in combination with a composition according to the invention, consists of a mixed family antineoplastics means selected from the group consisting of alpha-carotene, alpha-deformalisation, azitretina, AD-5 (Biotec), AHC-52 (Kyorin), alstonia, amonafide, ampline, amsacrine, angiostatin, Antinomian, antineoplaston a10,antineoplaston A2, antineoplaston A3, antineoplaston A5, antineoplaston AS2-1, APD (Henkel), aphidicolin of glycinate, asparaginase, avarol, baccarini, brazilin, enflurane, benzodepa, BIM-23015 (Ipsen-Beaufour), bisantrene, BMY-40481 (Bristol-Myers), boron-10 (Vestar), bromoacetamide, BW-502 (Wellcome), BW-773 (Wellcome), caracemide, Carmelite hydrochloride, CDAF (Ajinomoto), chlorosulfonation, CNH-2053 (Chemex), CNH-100 (Chemex), CI-921 (Warner-Lambert), CI-937 (Warner-Lambert), CI-941 (Warner-Lambert), CI-958 (Warner-Lambert), centenera, clairedelune, connection 1259 (ICN), compounds 4711 (ICN), kontrakan, CPT-11 (Yakult Honsha), krishnalila, curaderm, cytochalasin, tsitarabina, Cicolina, D-609 (Merz), DABIS maleate, dacarbazine, dellirium, didemnin-In, simple ester dihematoporphyrin, dihydroindolone dynaline, distamycin, DM-341 (Toyo Pharmar), DM-75 (Toyo Pharmar), DN-9693 (Daiichi Seiyaku), ethipramine, elliptinium acetate, ERMTS (Tsumura), ergotamine, etoposide, etretinate, phenetidine, FR-57704 (Fujisawa), gallium nitrate, genkwanin, GLA-43 (Chugai), GR-63178 (Glaxo), grifolan NMF-5N, hexadecylphosphocholine, BUT-221 (Green Cross), homoharringtonine, hydroxyacetone, ICRF-187 (BTG), ilmofosine, isoglutamine, isotretinoin, JI-36 (Otsuka), 477 (Ramot), K-76 COONa (Otsuak), AM (Kureha Chemical), KI-8110 (Corp), L-623 (American Cyanamid), laborelena, lonidamine, LU-23-112 (Lundbeck), LY-186641 (Lilly), MAP (NCI (US), maritina, MDL-27048 (Merrel Dow), MEDR-340 (Medco), barbarona, derivatives of merocyanine, methylenedianiline, MGI-136 (Molecular Genetics), inactivity, mitonafide, methadone, m is pignola, motretinide, MST-16 (Zenyaku Kogyo), N-(retinol)amino, N-021 (Nisshin Flour Milling), N-acylated dehydroalanine, nafazatrom, NCU-190 (Taisho), derived nocodazole, normosang, NSC-145813 (NCI), NSC-361456 (NCI), NSC-604782 (NCI), NSC-95580 (NCI), octreotide, ONO-112 (Ono), aquitanien, Org-10172 (Akzo), pancratistatin, patellifera, PD-111707 (Warner-Lambert), PD-115934 (Warner-Lambert), PD-131141 (Warner-Lambert), PE-1001 (Pierre Fabre), peptide D (ICRT), piroxantrone, polyaminopropyl, polyprenol acid, porphyrin (Efamol), broumana, procarbazine, proglumide, protease nexin I (Invitron), RA-700 (Tobishi), razoxane, RBS (Sapporo Breweries), restrictin-R, realitiy, retinoic acid, RP-49532 (Rhone-Poulenc), RP-56976 (Rhone-Poulenc), SK&F 104864 (SmithKline), SM-108 (Sumitomo), SMANCS (Kuraray), SP-10094 (SeaPharm), spatola, derived spirocyclopropane, spirogermanium, SS-554 (Unimed SS Pharmaceutical), lipoldino, stipoldione, SUN 0237 (Suntory), SUN 2071 (Suntory), superoxide dismutase, T-506 (Toyama), T-680 (Toyama), Taxol, TEI-0303 (Teijin), teniposide, calibratin, TJB-29 (Eastman Kodak), tocotrienols, Topolino, TT-82 (Teijin), UCN-01 (Kyowa Hakko), UCN-1028 (Kyowa Hakko), Ukraine, USB-006 (Eastman Kodak), vinblastine sulfate, vincristine, vindesine, fenestrated, vinorelbine, ventricosa, ventricina, withanolides and YM-534 (Yamanouchi).

Examples of radioprotective agents that can be used in combination chemotherapy of the present invention, include AD-5, adnon, the analogues of amifostine, detox, dimasa, 1-102, MM-159, N-acylated dehydroalanine, TGF-Gnentech, ciprocinol, amifostine, WR-151327, FUT-187, percutaneous Ketoprofen, nabumetone, superoxide dismutase (Chiron) and superoxide dismutase (Enzon).

Thus, in an additional preferred embodiment, the specified antineoplastics means selected from the group consisting of 5-FU-fibrinogen, centifolias acid, aminothiadiazole, brequinar sodium, carmofur, CGP-30694 (Ciba-Geigy), cyclopentylamine, tsitarabina phosphate-stearate, conjugates of cytarabine, DATHF (Lilly), DDFC (Merrel Dow), deazaguanine, dideoxycytidine, deocsa, DMDC (Yoshitomi), doxifluridine, EHNA (Wellcome), EX-015 (Merck & Co.), fazarabine, floxuridine, fludarabine phosphate, 5-fluorouracil, N-(2'-furandi)-5-fluorouracil, FO-152 (Daiichi Seiyaku), isopropylpyrazine, LY-188011 (Lilly), LY-264618 (Lilly), metabasepath, methotrexate, MZPES (Wellcome), nonspermicidal, NSC-127716 (NCI), NSC-264880 (NCI), NSC-39661 (NCI), NSC-612567 (NCI), PALA (Warner-Lambert), pentostatin, piritrexim, plicamycin, PL-AC (Asahi Chemical), TAC-788 (Takeda), Tg, tesofensine, TIF (Erbamont), trimetrexate, tyrosine kinase inhibitors, inhibitors tyrosinemia protein kinase, UFT (Taiho), andritsaina, 254-3 (Shionogi), analogues of aldophosphamide, altretamina, anxiron, BBR-2207 (Boehringer Mannheim), astroballe, budotitane, SA-102 (Wakunaga), carboplatin, carmustine, Chinoin-139, Chinoin-153, hlorambuzila, cisplatin, cyclophosphamide, CL-286558 (American Cyanamid), CY-233 (Sanofi), cisplatina, D-19-384 (Degussa), DACHP(Myr)2 (Sumimoto), diphenylpyraline, cites the Atik diplotene, derivatives distamycin DWA-2114R (Erba Chugai), E (ITI), elastin, FCE-24517 (Erbamont), estramustine phosphate, fotemustine, G-6-M (Unimed), GYKI-17230 (Chinoin), gasulla, ifosfamide, iproplatin, lomustina, mafosfamide, mitolactol, NK-121 (Nippon Kayaku), NSC-264395 (NCI), NSC-342215 (NCI), oxaliplatin, PCNU (decision Upjohn), prednimustine, push to talk-119 (Proter), ranimustine, semustine, SK&F-101772 (SmithKline), SN-22 (Yakult Honsha), spiramycin, TA 077 (Tanabe Seiyaku), tautomycin, temosolomida, taraxerone, tetrapedia, timelabel, 4181-A (Taiho), aclarubicin, actinomycin D, actinoplanes, ADR-456 (Erbamont), derived aerolysin, AN-201-11 (Ajinomoto), AN-3 (Ajinomoto), anisomycin (Nippon Soda), anthracycline, sinomenine, boukabara, BL-6859, Bristol-Myers), BMY-25067, Bristol-Myers), BMY-25551, Bristol-Myers), BMY-26605 (Bristol-Myers), BMY-27557 (Bristol-Myers), BMY-28438 (Bristol-Myers), bleomycin sulfate, zorubicin, alpha-carotene, alpha-deformalisation, azitretina, AD-5 (Biotec), ANS-52 (Kyorin), alstonia, amonafide, ampline, amsacrine, angiostatin, Antinomian, antineoplaston a10, antineoplaston A2, antineoplaston A3, antineoplaston A5, antineoplaston AS2-1, APD (Henkel), aphidicolin of glycinate, asparaginase, avarol, baccarini, brazilin, enflurane, benzodepa, BIM-23015 (Ipsen-Beaufour), bisantrene, BMY-40481 (Bristol-Myers), boron-10 (Vestar), bromoacetamide, BW-502 (Wellcome), BW-773 (Wellcome), caracemide, Carmelite hydrochloride, CDAF (Ajinomoto), chlorosulfonation, CNH-2053 (Chemex), CHX-100, CI-921 (Warner-Lambert), CI-937 (Warner-Lambert), CI-941 (Warner-Lambert),CI-958 (Warner-Lambert), centenera, clairedelune, connection 1259 (ICN), compounds 4711 (ICN), kontrakan, CPT-11 (Yakult Honsha), krishnalila, curaderm, cytochalasin, tsitarabina, Cicolina, D-609 (Merz), DABIS maleate, dacarbazine, dellirium, didemnin-In, simple ester dihematoporphyrin, dihydroindolone dynaline, distamycin, DM-341 (Toyo Pharmar), DM-75 (Toyo Pharmar), DN-9693 (Daiichi Seiyaku), ethipramine, elliptinium acetate, ERMTS (Tsumura), ergotamine, etoposide, etretinate, phenetidine, FR-57704 (Fujisawa), gallium nitrate, genkwanin, GLA-43 (Chugai), GR-63178 (Glaxo), grifolan NMF-5N, hexadecylphosphocholine, BUT-221 (Green Cross), homoharringtonine, hydroxyacetone, ICRF-187 (BTG), ilmofosine, isoglutamine, isotretinoin, JI-36 (Otsuka), K-477 (Ramot), K-76 COONa (Otsuak), K-AM (Kureha Chemical), KI-8110 (PLACES Corp), L-623 (American Cyanamid), laborelena, lonidamine, LU-23-112 (Lundbeck), LY-186641 (Lilly), MAP (NCI (US), maritina, MDL-27048 (Merrel Dow), MEDR-340 (Medco), barbarona, derivatives of merocyanine, methylenedianiline, MGI-136 (Molecular Genetics), inactivity, mitonafide, methadone, mopidamol, motretinide, MST-16 (Zenyaku Coduo), N-(retinol)amino, N-021 (Nisshin Flour Milling), N-acylated dehydroalanine, nafazatrom, NCU-190 (Taisho), derived nocodazole, normosang, NSC-145813 (NCI), NSC-361456 (NCI), NSC-604782 (NCI), NSC-95580 (NCI), octreotide, ONO-112 (Ono), aquitanien, Org-10172 (Akzo), pancratistatin, patellifera, PD-111707 (Warner-Lambert), PD-115934 (Warner-Lambert), PD-131141 (Warner-Lambert), PE-1001 (Pierre Fabre), peptide D (ICRT), piroxantrone, polyaminopropyl, polyrey the OIC acid, porphyrin (Efamol), broumana, procarbazine, proglumide, protease nexin I (Invitron), RA-700 (Tobishi), razoxane, RBS (Sapporo Breweries), restrictin-R, realitiy, retinoic acid, RP-49532 (Rhone-Poulenc), RP-56976 (Rhone-Poulenc), SK&F 104864 (SmithKline), SM-108 (Sumitomo), SMANCS (Kuraray), SP-10094 (SeaPharm), spatola, derived spirocyclopropane, spirogermanium, SS-554 (Unimed SS Pharmaceutical), lipoldino, stipoldione, SUN 0237 (Suntory), SUN 2071 (Suntory), superoxide dismutase, T-506 (Toyama), T-680 (Toyama), Taxol, TEI-0303 (Teijin), teniposide, calibratin, TJB-29 (Eastman Kodak), tocotrienols, Topolino, TT-82 (Teijin), UCN-01 (Kyowa Hakko), UCN-1028 (Kyowa Hakko), Ukraine, USB-006 (Eastman Kodak), vinblastine sulfate, vincristine, vindesine, fenestrated, vinorelbine, ventricosa, ventricina, withanolides, YM-534 (Yamanouchi), AD-5, Athena, analogues of amifostine, detox, dimasa, 1-102, MM-159, N-acylated dehydroalanine, TGF (Genentech), teprotide, amifostine, WR-151327, FUT-187, percutaneous Ketoprofen, nabumetone and superoxide dismutase.

The advantage of the compositions according to the invention is the use of supercritical extraction, innovative technologies for the extraction of herbs at low temperature without the use of industrial chemical solvents. This extraction process allows us to achieve high efficiency of the active components in the extracts, 250 times the effectiveness of the original fresh plant material.

In table 1 represent the go a preferred implementation of oral administration of compounds excluding inactive ingredients, as it was used in the method according to the invention. The quantities shown in table 1, represent a preferred dose of the listed ingredients.

Table 1
GrassThe type of extractPart of the plantAmount (mg)
Rosemarysupercriticalsheet100
Rosemaryalcohol (23% TRA of 34.5 mg)sheet50
Turmericsupercritical (45% of turmerone - 4.5 mg)rhizome10
Turmericalcohol (7% curcumin - 7 mg)rhizome100
Gingersverkhkriticheskie (30% pungent compounds - 16.2 mg, 8% of zingiberene-4.3 mg)rhizome54
Gingeralcohol (3% pungent compounds - 1.4 mg)rhizome46
Holy Basilalcohol (2% orsolino acid - 2 mg)sheet100
Green teaalcohol (45% polyphenols - 45 mg)sheet100
Polygonum cuspidatum- alcohol (8% resveratrol - 6.4 mg)the root and rhizome80
Coptis Chinesealcohol (6% berberine - 2.4 mg)root40
Barberryalcohol (6% berberine - 2.4 mg)root40
Oreganosverkhkriticheskie (0,8% TRA - 0,32 mg)sheet40
Scutellaria baicalensis- alcohol (5:1)root 20

Preferably, the composition shown in table 1, also included olive oil extracity and yellow beeswax.

The methods according to the invention is used therapeutically effective amount of the active components mentioned above. These effective amounts should generally contain from about 0.1 MG to 100 mg of active agent per kilogram body weight of the patient per day. This effective amount can vary depending on the physical condition of the patient, and other factors well known to science. Moreover, it should be clear that the dosage of the active agents may be administered in single or split the dosage to achieve the desired therapeutic effect. Optionally, other therapeutic agent can be used according to the present invention.

The methods according to the invention using the composition, which preferably are introduced to patients with conventional pharmaceutical carriers. Such carriers are well known to specialists in this field and, in General, can be in solid or liquid form. Solid forms of pharmaceutical preparations which can be obtained in accordance with the method according to the invention include powders, tablets, dispersible granules, capsules and pills. In General, solid form p is aparatow may contain from about 5% to 90% of active funds mass.

A solid carrier can be one or more substances which may also act as solvents, flavorings, solubilization, lubricants, suspendida agents that bind or dezintegriruetsja tablets agents; it can also serve as a material for capsules. In powders, as a rule, use solid granular media in a mixture with the active viscous component. In tablets, the active component is mixed in appropriate proportions with the media, with, optionally, binding properties, and give the mixture the desired shape and size. Acceptable solid carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragakant, methylcellulose, sodium carboxymethylcellulose, low melting wax, cocoa butter and the like. The term "obtaining"as implied, includes a preparation of a preparation of the active component and an encapsulating material as a carrier, which is used for formation of capsules in which the active component (with another carrier or not) is surrounded by media and is, thus, in interaction with him. Also includes a wafer. Tablets, powders, pills and capsules can be used as solid dosage forms suitable for oral administration. E is whether this is required for reasons of convenience or at the request of the patient, pharmaceutical tablets obtained in accordance with the method according to the invention, can be manufactured in the form of chewable tablets, using methods well-known to specialists in this field.

Also considered acceptable carriers solid forms of the drug, which can be converted directly before use, to liquid form for oral and parenteral use. Such liquid forms include solutions, suspensions and emulsions. These solid forms of drugs most convenient for dosing and as such are used for the preparation of individual liquid doses of the drug. On the other hand, a convenient solid form can be used so that after transformation into liquid form can be obtained from several individual liquid doses by measuring the specific volumes of the liquid form of the drug with a syringe, teaspoon, or other measure of volume. When multiple liquid doses obtained in this way, it is desirable to store the unused portion of the above liquid doses at low temperature (e.g. in a refrigerator) in order to avoid possible decomposition. Solid forms of the drug, intended to become the liquid form may contain, in addition to the active material, flavorings, colorants, the camera is the catalysts, buffers, artificial and natural sweeteners, dispersing agents, thickeners, soljubilizatory and the like. The liquid used to obtain a desired liquid forms of the drug may be water, isotonic water, ethanol, glycerin, propylene glycol and similar compounds as well as mixtures thereof. Naturally, the liquid used should be selected in accordance with the method of application. For example, liquid preparations containing large amounts of ethanol are not suitable for parenteral use.

The pharmaceutical preparation may be in unit dosage form. In such form the preparation is divided into unit doses containing certain quantities of the active component. The unit dosage form can be a packaged preparation, the package containing various amounts of the drug, for example, packaging of tablets, capsules, and powders in vials or ampoules. The unit dosage form can also be itself capsule, pill or tablet, or it may be a certain number of them in Packed form.

The pharmaceutical preparations according to the invention may include one or more preservatives, is well known to specialists in this field, such as benzoic acid, sorbic acid, methylparaben, propylparaben and ethylenediaminetetra Usna acid (EDTA). Preservatives are usually present in amounts up to 1% and preferably from about 0.05 to 0.5% by weight of the pharmaceutical compounds.

Suitable buffers for the compounds according to the invention include citric acid-sodium citrate, phosphoric acid-sodium phosphate and acetic acid-sodium acetate in amounts up to 1% and preferably from about 0.05 to 0.5% by weight of the pharmaceutical compounds. Applicable suspendresume agents or thickeners include products of cellulose, such as methylcellulose, carragenan, such as alginic acid and its derivatives, xanthan resin, gelatin, gum and microcrystalline cellulose in amounts up to 20% and preferably from about 1% to 15% by weight of the pharmaceutical compounds.

Sweeteners that can be used, include both artificial and natural sweeteners, well known to specialists in this field. Sweeteners such as monosaccharides, disaccharides and polysaccharides such as xylose, ribose, glucose, mannose, galactose, fructose, dextrose, sucrose, maltose, partially hydrolyzed starch or dry corn syrup, and sugar alcohols such as sorbitol, xylitol, mannitol and mixtures thereof, can be used in amounts from about 10% to 60% and, preferably, from about 20% to 50% by weight of the pharmaceutical is a mini connection. Water-soluble artificial sweeteners such as saccharin and salts of saccharin, such as sodium or calcium, salts of cyclamate, Acesulfame-K, aspartame and the like, and mixtures thereof can be used in amounts of about from 0.001% to 5% by weight, of the pharmaceutical compounds.

Flavorings that can be used in pharmaceutical products according to the invention include both natural and artificial flavors, mint, such as peppermint, menthol, vanilla, artificial vanilla, chocolate, artificial chocolate, cinnamon, various fruit flavors, both individually and in mixtures, used in amounts from about 0.5% to 5% by weight, of the pharmaceutical compounds.

Dyes that may be used according to the invention include pigments which may be added in amounts up to 6% of the weight of the connection. The preferred pigment, titanium dioxide, may be added in amounts up to 1%. The dyes may include other dyes suitable for food, drug or cosmetic use, known as F.D.&C. dyes and the like. Such dyes are generally present in amounts up to 0.25% and preferably about from 0.05% to 0.2% by weight of the pharmaceutical compounds. A complete list of all F.D.& S. D.& C. dyes is their corresponding chemical structures may be found in Kirk-Othmer Encyclopedia of Chemical Technology, v.5, pp.857-884, the text of which is reproduced here as a reference.

Applicable solvents include alcohol, propylene glycol, polyethylene glycol and the like and can be used for dissolution of flavors. Dissolving agents are usually present in amounts up to 10% and preferably from about 2% to 5% by weight of the pharmaceutical compounds.

Lubricants that can be used if necessary in the soluble compounds include silicone oils or fluids, such as substituted and unsubstituted polysiloxane, for example, dimethylpolysiloxane, also known as Dimethicone. Can be used and other well-known lubricants.

It is not expected that the compositions used in the methods according to the invention will exhibit undesirable interactions with other synthetic or natural substances. As a consequence, the connection according to the invention can be used in combination with other compounds and compositions suitable for the treatment of neoplasia of the prostate. In particular, the compounds used. in the methods according to the invention can be administered in combination with other compounds according to the invention, other antineoplastics substances and the like.

The optimal pharmaceutical preparations can be determined by a specialist in this region is among the depending on circumstances, such as the method of application and the required dose. See, for example, "Remington''s Pharmaceutical Sciences, 18thed. (1990, Mack Publishing Co., Easton, PA 18042), pp.1435-1712, which is fully included here as a reference. Such drugs can influence the physical state, stability, degree of liberation in vivo and the degree of clearance in vivo therapeutic agents according to the invention.

Method(s) of introduction

Substances and compositions mainly administered orally in the form of capsules, tablets, aqueous suspensions or solutions. Tablets may contain carriers, such as lactose and corn starch, and/or lubricants such as magnesium stearate. Capsules may contain diluents, including lactose and dried corn starch. Aqueous suspensions can contain emulsifying and suspendresume agents in combination with the active ingredient. Forms for oral administration may also contain sweetening, flavoring, coloring agents, or combinations thereof. Pill use, drips or capsules, coated enteric, to increase stability and release in the intestinal tract to increase suction, is the best way of introduction, currently under consideration.

Dosage

Dosing levels in the range from about 0.001 mg to 100 mg of the active ingredient of the matter is whether the composition per kilogram of body weight applicable to the treatment under the above conditions, preferred levels dosage range from 200 mg / day to 1600 mg per day. Substances and compounds according to the invention may generally be administered in two or three doses daily. The preferred strategy is to initiate treatment with low doses (200-300 mg) twice a day and slowly increase the dose, if necessary. The amount of active ingredient that may be associated with materials native to a unit dosage form may vary depending on the patient and the specific conditions of use.

It is clear, however, that the specific dose level for each individual patient will depend on many factors, including the activity of the used specific substances; the age, body weight, General health, sex and diet of the patient; the time of administration; the degree of excretion; the drug combination; the severity of the disorders to be treated; and the form of administration. An ordinary person skilled in the art should consider the variety of these factors and are able to set specific levels dosage of no more than routine experimentation.

EXAMPLES

The following examples are an illustration of the method according to the invention and not intended to be limiting thereof. Unless otherwise indicated, all percentages are based on 100% by weight of the final component is icii.

EXAMPLE 1

Obtaining compositions according to the invention

The composition of the invention is produced by methods known in this field and described in the application for the grant of U.S. patent No. 6387416 the present applicant. The contents of U.S. patent No. 6387416 fully included here as a reference. Obtaining components of the compositions according to the invention is summarized as follows.

The hydroalcoholic extract of ginger used in the composition according to the invention is preferably prepared as follows.

Ginger rhizome, which is preferably crushed for cryogenic preservation resistant to heat components, is subjected to supercritical extraction to obtain: (i) extract in the form of oil, here called "supercritical extract, ginger contains volatile lipophilic components and (ii) do not contain oil residue. Does not contain oil residue then extracted in a mixture of water/alcohol, preferably water/ethanol containing 60 to 80 parts of alcohol and 40-20 parts of water. A solution of the alcohol/water is then evaporated, leaving a powdery residue of the extract, called here "the hydroalcoholic extract of ginger.

The composition according to the invention should preferably contain supercritical ginger extract and hydroalcoholic extract of ginger in a mass ratio of from about 0.9 to 1.4 parts, more PR is doctitle from about 1.1 to 1.3 parts most preferably approximately 1.17 parts of the supercritical extract of ginger to 1 part of the hydroalcoholic extract of ginger.

Supercritical extracts of ginger, rosemary, turmeric and oregano used in the compositions according to the invention, can be obtained in accordance with known methods, supercritical extraction, as described, for example, in E. Stahl, K.W.Quirin, D. Gerard, Dense Gases for Extraction and Refining, Springer Verlag 4 1988, included here as a reference.

Hydroalcoholic extracts of rosemary, turmeric, Basilica of the sacred, Polygonum cuspidatum, coptis Chinese, barberry and Scutellaria baicalensis used in the compositions according to the invention, can be obtained in accordance with generally accepted ways hydroalcoholic extraction. For example, the hydroalcoholic extracts can be obtained by extracting portions of the plants in a mixture of water/alcohol (preferably water/ethanol), preferably containing from 60 to 80 parts of alcohol and 40-20 parts water) and then by evaporation of a solution of the alcohol/water, leaving a powdery residue extract (called here "the hydroalcoholic extract").

In the composition according to the invention the hydroalcoholic extract of turmeric and supercritical extract of turmeric should preferably be contained in a weight ratio of from about 8 to 12 parts, more preferably from about 9 to 11 parts, most preferably the ome 10 parts of a hydroalcoholic extract to 1 part of supercritical extract.

The composition according to the invention should preferably contain supercritical rosemary extract and hydroalcoholic extract of rosemary in a mass ratio of from about 1.6 to 2.4 parts, more preferably from about 1.8 to 2.2 parts, most preferably about 2.0 parts supercritical extract to 1 part of the hydroalcoholic extract.

The hydroalcoholic extract of ginger used in the composition according to the invention should preferably contain from about 2.4% to 3.6 percent, more preferably from about 2.7% to 3.3% and most preferably about 3.0 percent burning substances, by mass (for example, shogaol).

Supercritical extract of ginger used in the composition according to the invention should preferably contain from about 24% to 36%, more preferably from about 27% to 33%, and most preferably about 30% pungent substances, by mass (for example, shogaol) and preferably from about 6.4% to about 9.6%, more preferably from about 7.2% to 8.8 percent, and most preferably about 8% zingiberene, mass.

Supercritical extract of turmeric used in the composition according to the invention should preferably contain from about 36% to 54%, more preferably from about 40.5 percent to 49.5%, and most preferably about 45% of turmerone, mass.

Supercritical extract of rosemary, the use of which has been created in the compositions according to the invention, should preferably contain from about 18.4% to 27.6%and, more preferably approximately from 20.7% to 25.3%, and most preferably about 23% total phenolic antioxidants ("TRA"), mass.

Supercritical extract of oregano used in the composition according to the invention should preferably contain from about 0.64% to 0.96%, and more preferably from about 0.72% up to 0.88%, and most preferably about 0.8% TRA, mass.

The hydroalcoholic extract of turmeric used in the composition according to the invention should preferably contain from about 5.6% to 8.4%, and more preferably from about 6.3% to 7.7 percent, and most preferably about 7% curcumin, mass.

The hydroalcoholic extract of rosemary used in the composition according to the invention should preferably contain from about 18.4% to 27.6%and, more preferably approximately from 20.7% to 25.3%, and most preferably about 23% of TRA, mass.

The hydroalcoholic extract of the Basilica of the sacred, used in the composition according to the invention should preferably contain from about 1.6% to 2.4 percent, more preferably from about 1.8% to about 2.2%, and most preferably about 2% of ursolic acid, by mass.

The hydroalcoholic extract of green tea used in the composition according to the invention should preferably contain from about 36% to 54%, more pre is respectfully approximately 40.5 percent to 49.5%, and most preferably about 45% polyphenols, mass.

Hydroalcoholic extract of Polygonum cuspidatum used in the composition according to the invention should preferably contain from about 6.4% to about 9.6%, more preferably from about 7.2% to 8.8 percent, and most preferably about 8% resveratrol, mass.

A hydroalcoholic extract of coptis Chinese, used in the composition according to the invention should preferably contain from about 4.8% to about 7.2%, more preferably from about 5.4% to 6.6 percent, and most preferably about 6% berberine, mass.

The hydroalcoholic extract of barberry used in the composition according to the invention should preferably contain from about 4.8% to about 7.2%, more preferably from about 5.4% to 6.6 percent, and most preferably about 6% berberine, mass.

EXAMPLE 2

The effect of the compositions according to the invention on the cells of cancer of the prostate

Received a series of dilutions of the composition according to the invention in DMSO, and the dilution was added to the growth medium LNCaP, so that all the tested doses were equivalent (0,1%) levels of DMSO. Growth curves of cells was obtained by counting cells after 24, 48 and 72 hours and compared them with control cells treated in the same time intervals only 0.1% DMSO. Apoptosis in these cultures was assessed by Western blot analysis of PARP cleavage and u is the activity of caspase-3 using a colorimetric analysis of the substrate.

Effects on the activity of purified enzyme SOH-2 was measured by colorimetric analysis, and effects on the expression of protein-SOH-2 was determined by Western blot analysis of protein extracts from treated cells. Activity was also compared with the effects of purified curcumin dissolved in DMSO, at levels equivalent to those that were found in the compositions according to the invention in similar doses.

The growth of LNCaP cells was suppressed by the compositions according to the invention, and after 72 hours was observed in 78%reduction in the number of cells in the treated cultures (7,9×104against of 3.53×105cells per well, p=0.01) compared with controls. Fragments of PARP cleavage were obvious, and the activity of caspase-3 was positively regulated by 2 times by processing within 72 hours, with the demonstration of apoptotic actions not detected in control. Activity SOH-2 also decreased significantly in the presence of the compositions according to the invention, while an equivalent dose of curcumin does not inhibit SOH-2 used in the analysis. The expression of MOR protein-2 in LNCaP cells not exposed to.

The results of this example are shown in figures 1-5.

These results demonstrate that the compositions according to the invention strongly inhibit LNCaP cells and induce apoptosis. It turns out that these effects are more mo is tion, than those observed for the same curcumin, demonstrating synergy between the extracts used in the compositions according to the invention.

EXAMPLE 3

The effect of the compositions according to the invention in the pre-malignant neoplasia of the prostate

Presents the patient for the treatment of pre-malignant neoplasia of the prostate. The composition according to the invention was administered to a given patient during the course of treatment, which lasts for several weeks, which did not lead to significant side effects. The patient noted the treatment of cell growth neoplasia and loss of existing cell neoplasia, neoplasia was not detected.

EXAMPLE 4

The effect of the compositions according to the invention on epithelioma prostate

Presents the patient for the treatment of epithelioma prostate cancer stage, confirmed elevated PSA, manual evaluation and biopsy of the tumor. The composition according to the invention were administered the indicated patient a course of treatment lasting a few months that did not lead to significant side effects. The patient noted an appeal the growth of tumor cells, destruction of existing cancer cells and reduce tumor size, and absence of metastasis of the tumor. With continued treatment, the patient continued absence of symptoms W the ranks of the symptoms of neoplasia of the prostate, the lack of long-term side effects of treatment and the absence of tumor metastases.

Thus, after the description of the invention it will be obvious that it may be modified or changed in many ways. Such modifications and variations are not considered as a deviation from the essence and scope of the invention, and assumes that all such modifications and variations are included in the scope of the following claims.

1. Method for the treatment or prevention of neoplasia of the prostate in a subject, comprising the stage of introduction of a specified subject an effective amount of a composition for the treatment or prevention of a specified neoplasia of the prostate gland, and the specified composition comprises therapeutically effective amounts of supercritical extracts of rosemary, turmeric, oregano and ginger; and therapeutically effective amounts of hydroalcoholic extracts of the Basilica of the sacred, ginger, turmeric, Scutellaria baicalensis, rosemary, green tea, Polygonum cuspidatum, coptis Chinese and barberry, provided that the specified neoplasia of the prostate is not intraepithelial neoplasia of the prostate gland.

2. The method according to claim 1, in which the above composition is administered orally.

3. The method according to claim 2, in which the composition for oral administration is in the form of one or more capsules, one who does a few tablets, or one or more pills.

4. The method according to claim 1, wherein the composition comprises:
(A) from about 4.5 to 7.5% by weight of the hydroalcoholic extract of ginger;
(B) from about 5.5 to 8.5% by weight of the supercritical extract of ginger;
(C) from about 1.0 to 1.5% by weight of the supercritical extract of turmeric;
(D) from about 10.0 to 16.0% of the weight of the supercritical extract of rosemary;
(E) from about 4.0 to 6.0 percent by weight of the supercritical extract of oregano;
(F) from about 10.0 to 16.0% of by weight of the hydroalcoholic extract of turmeric;
(G) from about 5.5 to 8.0 per cent by weight of the hydroalcoholic extract of rosemary;
(H) from about 10.0 to 16.0% of by weight of the hydroalcoholic extract of the Basilica of the sacred;
(I) from about 10.0 to 16.0% of by weight of the hydroalcoholic extract of green tea;
(J) about from 8.0 to 12.0% by weight of the hydroalcoholic extract of Polygonum cuspidatum;
(K) from about 4.0 to 6.0 percent by weight of the hydroalcoholic extract of coptis Chinese;
(L) from about 4.0 to 6.0 percent by weight of the hydroalcoholic extract of barberry; and
(M) from about 2.0 to 3.0 percent by weight of the hydroalcoholic extract of Scutellaria baicalensis.

5. The method according to claim 1, wherein the mass ratio of the supercritical extract of ginger to the hydroalcoholic extract of ginger is approximately from 0.9:1 to 1.4:1.

6. The method according to claim 1, wherein the mass ratio of the hydroalcoholic extract of turmeric to the supercritical extract of the turmeric is from about 8:1 to 12:1.

7. The method according to claim 1, wherein the mass ratio of the supercritical extract of rosemary to the hydroalcoholic extract of rosemary is about 1.6:1 to 2.4:1.

8. The method according to claim 1, wherein the hydroalcoholic extract of ginger is from about 2.4 to 3.6 per cent by weight of pungent compounds.

9. The method according to claim 1, in which the supercritical extract of ginger contains approximately 24 to 36% by weight of pungent compounds and from about 6.4 to 9.6 percent by weight of zingiberene.

10. The method according to claim 1, in which the supercritical extract of turmeric contains from about 36 to 54% by weight of turmerone.

11. The method according to claim 1, in which supercritical rosemary extract contains approximately 18.4 27.6% by weight of all phenolic antioxidants.

12. The method according to claim 1, in which the supercritical extract of oregano contains approximately from 0.64 to 0.96% by weight of all phenolic antioxidants.

13. The method according to claim 1, wherein the hydroalcoholic extract of turmeric contains from about 5.6 to 8.4 per cent by weight of curcumin.

14. The method according to claim 1, wherein the hydroalcoholic extract of rosemary contains approximately 18.4 27.6% by weight of all phenolic antioxidants.

15. The method according to claim 1, wherein the hydroalcoholic extract of the Basilica of the sacred contains approximately from 1.6 to 2.4% by weight of ursolic acid.

16. The method according to claim 1, wherein the hydroalcoholic extract of green tea contains about 36 to 54% by weight is of olivenol.

17. The method according to claim 1, wherein the hydroalcoholic extract of Polygonum cuspidatum contains from about 6.4 to 9.6 percent by weight of resveratrol.

18. The method according to claim 1, wherein the hydroalcoholic extract of coptis Chinese contains from about 4.8 to 7.2 per cent by weight of berberine.

19. The method according to claim 1, wherein the hydroalcoholic extract of barberry contains from about 4.8 to 7.2 per cent by weight of berberine.

20. The method according to claim 1, in which the specified composition is provided on the stage (a), provides:
(A) from about 4.5 to 7.5% by weight of the hydroalcoholic extract of ginger, where the extract contains from about 2.4 to 3.6 per cent by weight of pungent compounds;
(B) from about 5.5 to 8.5% by weight of the supercritical extract of ginger, where the extract contains from about 24 to 36% by weight of pungent compounds and from about 6.4 to 9.6 percent by weight of zingiberene;
(C) from about 1.0 to 1.5% by weight of the supercritical extract of turmeric, where the extract contains from about 36 to 54% by weight of turmerone;
(D) from about 10.0 to 16.0% of the weight of the supercritical extract of rosemary, where the extract contains approximately 18.4 27.6% by weight of all phenolic antioxidants;
(E) from about 4.0 to 6.0 percent by weight of the supercritical extract of oregano, where the extract contains approximately from 0.64 to 0.96% by weight of all phenolic antioxidants;
(F) from about 10.0 to 16.0% of by weight of the hydroalcoholic extract of turmeric, where the extract contains the example is about from 5.6 to 8.4% by weight of curcumin;
(G) from about 5.5 to 8.0 per cent by weight of the hydroalcoholic extract of rosemary, where the extract contains approximately 18.4 27.6% by weight of all phenolic antioxidants;
(H) from about 10.0 to 16.0% of by weight of the hydroalcoholic extract of the Basilica of the sacred, where the extract contains approximately from 1.6 to 2.4% by weight of ursolic acid;
(I) from about 10.0 to 16.0% of by weight of the hydroalcoholic extract of green tea, where the extract contains from about 36 to 54% by weight of polyphenols;
(J) about from 8.0 to 12.0% by weight of the hydroalcoholic extract of Polygonum cuspidatum, where the extract contains from about 6.4 to 9.6 percent by weight of resveratrol;
(K) from about 4.0 to 6.0 percent by weight of the hydroalcoholic extract of coptis Chinese, where the extract contains from about 4.8 to 7.2 per cent by weight of berberine;
(L) from about 4.0 to 6.0 percent by weight of the hydroalcoholic extract of barberry, where the extract contains from about 4.8 to 7.2 per cent by weight of berberine; and
(M) from about 2.0 to 3.0 percent by weight of the hydroalcoholic extract of Scutellaria baicalensis;
and where the specified composition additionally contains
(i) supercritical extract of ginger and the hydroalcoholic extract of ginger in a mass ratio of about 0.9 to 1.4 parts supercritical extract to 1 part postsurgical hydroalcoholic extract;
(ii) the hydroalcoholic extract of turmeric and supercritical extract of turmeric in mass against the AI, approximately 8 to 12 hydroalcoholic extract per 1 part of supercritical extract; and
(iii) supercritical rosemary extract and hydroalcoholic extract of rosemary in a mass ratio of about 1.6 to 2.4 parts supercritical extract per 1 part of the hydroalcoholic extract.

21. The method according to claim 1, wherein the composition is administered in a daily dose of at least approximately 700 mg.

22. The method according to claim 1, in which the above composition is administered on a daily basis, at least within 4 weeks.

23. A method of treating at least one malignant tumor of the prostate in a patient, comprising the stage of introduction of a specified subject an effective amount of the composition for treatment of the indicated tumor, and this composition contains therapeutically effective amounts of supercritical extracts of rosemary, turmeric, oregano and ginger; and therapeutically effective amounts of hydroalcoholic extracts of the Basilica of the sacred, ginger, turmeric, Scutellaria baicalensis, rosemary, green tea, Polygonum cuspidatum, coptis Chinese and barberry.

24. The method according to item 23, in which the above composition is administered orally.

25. The method according to paragraph 24, in which the composition for oral administration are presented in the form of one or more capsules, one or more tablets, or odnosili few pills.

26. The method according to item 23, in which the composition contains:
(A) from about 4.5 to 7.5% by weight of the hydroalcoholic extract of ginger;
(B) from about 5.5 to 8.5% by weight of the supercritical extract of ginger;
(C) from about 1.0 to 1.5% by weight of the supercritical extract of turmeric;
(D) from about 10.0 to 16.0% of the weight of the supercritical extract of rosemary;
(E) from about 4.0 to 6.0 percent by weight of the supercritical extract of oregano;
(F) from about 10.0 to 16.0% of by weight of the hydroalcoholic extract of turmeric;
(G) from about 5.5 to 8.0 per cent by weight of the hydroalcoholic extract of rosemary;
(H) from about 10.0 to 16.0% of by weight of the hydroalcoholic extract of the Basilica of the sacred;
(I) from about 10.0 to 16.0% of by weight of the hydroalcoholic extract of green tea;
(J) about from 8.0 to 12.0% by weight of the hydroalcoholic extract of Polygonum cuspidatum;
(K) from about 4.0 to 6.0 percent by weight of the hydroalcoholic extract of coptis Chinese;
(L) from about 4.0 to 6.0 percent by weight of the hydroalcoholic extract of barberry; and
(M) from about 2.0 to 3.0 percent by weight of the hydroalcoholic extract of Scutellaria baicalensis.

27. The method according to item 23, in which at least one malignant tumor in the specified subject is detected during surgery of the prostate, and this tumor was not detected by the doctor during a medical examination of a given entity.

28. The method according to item 23, in which at least one malignant tumor of the specified entity is limited to the prostate gland and can be detected by a doctor during a medical examination of the specified entity.

29. The method according to item 23, in which a malignant tumor with respect to the specified at least one malignant tumor extends the specified entity outside the capsule of the prostate, but does not apply in the specified subject in the lymph nodes.

30. The method according to item 23, in which a malignant tumor with respect to the specified at least one malignant tumor METAS GATHERUM in regional lymph nodes or other parts of the body of the specified entity.

31. A method of treatment of complications associated with the presence of the subject has neoplasia prostate cancer, including the stage of introduction of a specified subject an effective amount of a composition for the treatment of these complications, and the specified composition comprises therapeutically effective amounts of supercritical extracts of rosemary, turmeric, oregano and ginger; and therapeutically effective amounts of hydroalcoholic extracts of the Basilica of the sacred, ginger, turmeric, Scutellaria baicalensis, rosemary, green tea, Polygonum cuspidatum, coptis Chinese and barberry, where these complications selected from the group consisting of impaired libido or impaired sexual function on a temporary or permanent basis, impotence, stress due to disease or urinary incontinence.

32. The method according to p in which the ohms specified composition is administered orally.

33. The method according to p, in which the composition for oral administration are presented in the form of one or more capsules, one or more tablets, or one or more pills.

34. The method according to p, in which the composition contains:
(A) from about 4.5 to 7.5% by weight of the hydroalcoholic extract of ginger;
(B) from about 5.5 to 8.5% by weight of the supercritical extract of ginger;
(C) from about 1.0 to 1.5% by weight of the supercritical extract of turmeric;
(D) from about 10.0 to 16.0% of the weight of the supercritical extract of rosemary;
(E) from about 4.0 to 6.0 percent by weight of the supercritical extract of oregano;
(F) from about 10.0 to 16.0% of by weight of the hydroalcoholic extract of turmeric;
(G) from about 5.5 to 8.0 per cent by weight of the hydroalcoholic extract of rosemary;
(H) from about 10.0 to 16.0% of by weight of the hydroalcoholic extract of the Basilica of the sacred;
(I) from about 10.0 to 16.0% of by weight of the hydroalcoholic extract of green tea;
(J) about from 8.0 to 12.0% by weight of the hydroalcoholic extract of Polygonum cuspidatum;
(K) from about 4.0 to 6.0 percent by weight of the hydroalcoholic extract of coptis Chinese;
(L) from about 4.0 to 6.0 percent by weight of the hydroalcoholic extract of barberry; and
(M) from about 2.0 to 3.0 percent by weight of the hydroalcoholic extract of Scutellaria baicalensis.

35. The method according to p in which the specified subject to treatment complications include impaired sexual function.

36. The way to reduce the duration of the observations associated with the development of the subject has neoplasia prostate cancer, including the stage of introduction of a specified subject an effective amount of the composition, and this composition contains therapeutically effective amounts of supercritical extracts of rosemary, turmeric, oregano and ginger; and therapeutically effective amounts of hydroalcoholic extracts of the Basilica of the sacred, ginger, turmeric, Scutellaria baicalensis, rosemary, green tea, Polygonum cuspidatum, coptis Chinese and barberry.



 

Same patents:

FIELD: chemistry.

SUBSTANCE: invention relates to a method for regiospecific synthesis of rapamycin 42-ester derivatives of formula , where R is ketal isopropylidene substituted with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid, linear or branched C1-C10 alkyl, which possibly contains a halogen, C2-C8 alkenyl, or phenyl, where the said method involves acylation of 42-hydroxyrapamycin with an acyl donor in the presence of lipase. The invention also relates to regiospecific preparation of rapamycin 42-ester from ketal isopropylidene substituted with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid in the presence of lipase.

EFFECT: increased output of the product under mild conditions.

13 cl, 12 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel condensed heterocylic protein kinase modulators of formula I where L1 and L2 independently denote a bond, and R1 and R2 denote a substituted or unsubstituted heteroaryl or a substituted or unsubstituted aryl, as well as to pharmaceutical compositions containing such compounds, and methods of using the compounds to prepare medicine for diseases mediated by protein kinase activity.

EFFECT: increased effectiveness of using the compounds.

24 cl, 20 tbl, 24 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds selected from compounds of formulae Ia, lb and Ic, which have protein kinase activity on kinase selected from CDKs, Aurora, Jak2. Rock, CAMKI, FLT3, Tie2, TrkB, FGFR3 and KDR, abnormal activity of which is observed in pathological conditions such as nonmalignant and malignant proliferative diseases. In compounds of formulae , and : n equals 0 or 1, R1 is selected from a group comprising halogen, C1-C6alkyl, C1-C6alkoxy, halogen-substituted CpC6alkyl and halogen-substituted C1-C6alkoxy, R2 is selected from a group comprising phenyl, 6-member heteroaryl containing 1-2 nitrogen atoms in the heteroaryl ring as heteroatoms, and phenyl(C0-C4)alkyl, where the said phenyl and heteroaryl in R2 are optionally substituted with 1-3 radicals independently selected from a group comprising halogen, C1-C6alkyl, C1-C6alkoxy, halogen-substituted C1-C6alkyl, halogen-substituted C1-C6alkoxy, -S(O)0-2R5, -COOR5 and -NR5C(O)R6, where R5 is selected from C1-C6alkyl, and R6 is selected from phenyl, where the said phenyl in R6 is optionally substituted with 1-3 radicals independently selected from a group comprising C1-C6alkyl, C1-C6alkoxy, halogen-substituted C1-C6alkyl and halogen-substituted C1-C6alkoxy, X is selected from CR7 and N, where R7 is selected from hydrogen or C1-C6alkyl.

EFFECT: increased effectiveness of using the compounds.

7 cl, 3 dwg, 1 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to tetrahydropyridoindole derivatives of general formula , where R1, R2, R3 and R4 independently represent hydrogen; C1-C5alkyl, which can be optionally substituted and represents trifluoromethyl if C1-C5alkyl is substituted; C1-C3alkoxy or halogen, and R5 is C1-C6alkylcarbonyl, C1-C5alkylcarbamoyl, C1-C5alkoxycarbonyl, C2-C5alkenylcarbonyl, C3-C6cycloalkylcarbonyl, C3-C6cycloalkyl(C1-C3)alkylcarbonyl, C3-C6cycloalkylcarbamoyl, C3-C6cycloalkylthiocarbamoyl, phenylcarbonyl or phenyl(C1-C3)alkylcarbonyl, where the phenyl residue in these two groups contains one, two, three or four substitutes, independently selected from a group comprising C1-C4alkyl, C1-C3alkoxy, halogen, trifluoromethyl and trifluoromethoxy, monosubstituted with a C3-C6cycloalkyl group, or monosubstituted with a phenyl group which in turn is substituted with a C1-C3alkyl group; phenyl(C1-C3)alkoxycarbonyl, phenylcarbamoyl or phenylthiocarbamoyl (where these two groups are optionally independently monosubstituted with a C1-C5alkyl group or halogen atoms); phenyl(C1-C3)alkylcarbamoyl, phenyl(C1-C3)alkylthiocarbamoyl, biphenylcarbamoyl, naphthylcarbonyl, naphthyl(C1-C3)alkylcarbonyl or naphthylcarbamoyl (where the naphthyl residues in these three groups are optionally monosubstituted with substitutes independently selected from a group comprising C1-C3alkyl, C1-C3alkoxy and halogen); fluorenylcarbonyl, optionally substituted with an oxo group, fluorenyl(C1-C3)alkoxycarbonyl; or 5-9-member heteroarylcarbonyl groups containing one or two heteroatoms, independently selected from a group comprising oxygen, nitrogen and sulphur, where the said groups can be substituted with one or two groups independently selected from C1-C3alkyl and halogen, provided that if R1, R2, R3, R4 are hydrogen, R5 is not ethoxycarbonyl or tert-butoxycarbonyl, or salt thereof. The invention also relates to a pharmaceutical composition based on the compound of formula I and to use of the compound in preparing a medicinal agent.

EFFECT: obtaining novel tetrahydropyridoindole derivatives which have CRTH2 receptor antagonistic activity.

14 cl, 14 tbl, 171 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a free base (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)- ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine in crystalline form, having a powder X-ray diffraction pattern with peaks at diffraction angles (2θ) 15.7±0.1, 17.3±0.1 and 19.7±0.1. The invention also relates to a pharmaceutical composition, to methods of treating cancer in mammals, as well as to a method of treating abnormal cell growth in mammals in need of such treatment.

EFFECT: obtaining an novel biologically active compound having the said inhibitory activity.

12 cl, 1 ex, 3 tbl, 2 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to an agent, which is in form of fluorinated 1,4-naphthoquinone derivatives of general formula (I) which have cytotoxic effect on human cancer cells in a culture. In general formula (I) 1) R1=NHC(CH3)3, R2, R3=F; 2) R1=NHCH2CH2SCH3, R2, R3=F; 3) R1=N(CH2CH2)2, R2, R3=F; 4) R1=N(CH2CH2)2, R2, R3=F; 5) R1=NHCH2CH2CH2CH3, R2, R3=F; 6) R1=NHC6H5R2, R3=F; 7) R1=H(CH3)CH2CH2OH, R2, R3=F; 8) R1, R3=NHCH2CH2CH2CH3, R2=F; 9) R1=N(CH2CH2OH)2, R2, R3=F; 10) R1=NHC6H5, R2=CH3, R3=F; 11) R1=OCH3, R2, R3=F; 12) R1=NH(CH2)2SS(CH2)2NH(2-pentafluoro-1,4-naphthoqunonyl), R2, R3=F; 13) R1=NHC2H5, R2, R3=F; 14) R1=N+C5H5, R2=O; R3=F; 15) R1=NHCH2CH2OH, R2,R3=F; 16)R1, R2=OCH3, R3=F.

EFFECT: proposed compounds can be used in medicine as a base for designing drug formulations of preparations used in malignant growth therapy.

2 dwg, 4 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: testosterone is introduced intramuscularly and applied on the stomach and breast skin to ensure the steady high blood concentration. 6-8 hours prior to a session of gamma-ray teletherapy, a composite is introduced through rectum. The composite contains sodium alginate, dimethyl sulphoxide solution and testosterone. 6-8 hours later, the composite is removed from rectum. It is followed with gamma-ray teletherapy with "РОД" 5 Gy and local microwave hyperthermia.

EFFECT: method allows enhancing radio modifying treatment effect, inhibiting growth and metastasis of the tumour to the extent of regression, reducing number of by-effects and contraindications.

2 cl, 2 tbl, 1 ex

Oncotherapy // 2387456

FIELD: medicine.

SUBSTANCE: therapy involves introduction of sonicated human DNA combined with nonhistone protein to the patient with the length of human DNA fragments making 200-6000 pairs of bases, and the ratio of sonicated human DNA/nonhistone protein being 1/0.8. The complex is administered in a dose to ensure the blood concentration of sonicated human DNA 25 ng/ml - 1000 ng/ml.

EFFECT: application of the invention implies oncotherapy ensured by substitution of replacement oncolocus by a DNA fragment with nonmutant allele to form a nucleotide stable complex.

2 cl, 4 tbl, 11 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula Ia: and its pharmaceutically acceptable salt, where: p equals 0 or 1; n assumes values from 1 to 3, q equals 1; R5 is selected from hydrogen, -XNR7R8, pyrimidine-C0-4alkyl, pyridine-C0-4alkyl, phenyl, C3-10cycloalkyl-C0-4alkyl and C3-6heterocycloalkyl-C0-4alkyl, where C3-6heterocycloalkyl is a saturated monocyclic ring system containing the said number of atoms, provided that one or more of the said carbon atoms is substituted with O or NR, where R is hydrogen or C1-4alkyl; R7 and R8 represent C1-4alkyl; R6 denotes hydrogen; or R5 and R6 together with a nitrogen atom to which they are both bonded form morpholine or piperidine; where any piperdine-C0-4alkyl, piperidine-C0-4alkyl or C3-10cycloalkyl-C0-4alkyl of substitute R5 or a combination of radicals R5 and R6 can be optionally substituted with 1-2 radicals which are independently selected from -XNR7R8 and -XOR7, the said phenyl of substitute R5 is substituted with a -XR9 group, the said C3-6heterocycloalkyl-C0-4alkyl of substitute R5 is optionally substituted with a -XOR7 group, where X is a single bond or C1-4alkylene; R7 and R8 are independently selected from hydrogen and C1-4alkyl; R9 is selected from C3-10heterocycloalkyl which is a saturated monocyclic ring system containing the said number of atoms, provided that one or more of the said carbon atoms is substituted with O or NR, where R is as given above; R10 denotes hydrogen; R15 is selected from halogen, C1-6alkyl and C1-6alkoxy; and R16 is selected from halogen, methoxy, nitro, -NR12C(O)R13, -C(O)NR12R12, -NR12R12, -C(O)OR12 and -C(O)NR12R13; each R12 is selected from hydrogen and C1-6alkyl; R13 is selected from phenyl, thienyl, pyrazolyl, pyridinyl or isoxazolyl, where any phenyl, thienyl, pyrazolyl, pyridinyl or isoxazolyl of substitute R13 can be optionally substituted with 1-2 radicals which are independently selected from halogen, C1-6alkyl, halogen-substituted C1-6alkyl, imidazole-C0-4alkyl, C3-10cycloalkyl, C3-10heterocycloalkyl-C0-4alkoxy and C3-10heterocycloalkyl-C0-4alkyl; where the said C3-10heterocycloalkyl-C0-4alkoxy and C3-10heterocycloalkyl-C0-4alkyl each represent a saturated monocyclic ring system containing the said number of atoms, provided that one or more of the said carbon atoms is substituted with O or NR, where R assumes values given above; and the said C3-10heterocycloalkyl-C0-4alkoxy and C3-10heterocycloalkyl-C0-4alkyl can each be optionally substituted with 1 radical independently selected from C1-6alkyl, hydroxyl-substituted C1-6alkyl and NR7R8, where R7 and R8 assume values given above. The invention also relates to pharmaceutical compositions containing the said compounds.

EFFECT: obtaining novel compounds and compositions based on the said compounds which can be used in medicine for treating and preventing diseases or disorders associated with abnormal or uncontrolled kinase activity, particularly diseases or disorders associated with abnormal activity of kinase c-Src, FGFR3, KDR and/or Lck.

12 cl, 1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and biotechnology and concerns an anticancer drug based on nanoparticles bearing recombinant human tumour necrosis factor alpha. Substance of the invention includes the anticancer drug representing nanoparticles each of which contains a nucleus consisting of polynucleotide complex representing double-helical RNA (dhRNA) - an interferonogenesis inducer, and coated with a layer of spermidine conjugate with polyglucin held by ionic interaction between negative polynucleotide complex and positive spermidine, while recombinant human tumour necrosis factor alpha is covalently bound with activated polyglucin. As double-helical RNA, the anticancer drug contains double-helical RNA of Saccharomyces cerevisiae yeast. Nanoparticles are ball shaped and sized about 50-70 nm; 60-80 molecules of recombinant human TNF-α of cytolytic activity 106 ME/mg of protein and higher, 60-80 molecules of polyglucin and 1000-1300 molecules of spermidine are necessary for one molecule of double-helical RNA of Saccharomyces cerevisiae yeast.

EFFECT: reduced dose of TNF-α and lower toxicity.

5 cl, 5 ex, 4 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention belongs to food, chemical and pharmaceutical, medical, liquor and biotechnological industries. Previously washed in water and homogenously blended fruits of walnuts with pericarps are subjected to extraction. The prepared raw material is steeped in 35-45% water solution of ethyl alcohol in 1:1 weight ratio. The mixture is infused for 6-7 days away from light, then extracted with ultrasound in cavitation mode for 30-60 min at a temperature of 15-18°C; after that extraction is repeated at least 5-6 times, each subsequent extaction being carried out after the mixture has been infused for 3-4 days max. Eventually, the extract is separated by filtration and cooled.

EFFECT: increased content of biologically active substances in a supplement.

3 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention is a pharmaceutical composition for psoriasis and eczema treatment, containing trailing mahonia extract in loposomal delivery system. The extract content in the composition is 5-20% of the composition total weight. The invention also concerns method for production of trailing mahonia extract.

EFFECT: pharmaceutical composition is especially effective for psoriasis and eczema treatment among patients of various degrees of disease.

8 cl

FIELD: medicine, veterinary science.

SUBSTANCE: invention concerns veterinary medicine. Treatment-and-preventive agent for young farm animals is alcoholic tincture of vegetable raw material, the raw material being a mixture of grass and blossom cluster of purple Echinacea, coltsfoot, Syrian rue grass and licorice roots. The vegetable raw material is steeped in 70% ethyl alcohol in proportion 1:10, then kept in dark room at a temperature of 15-20°C for 7 days, strained. The raw material is press out and the tincture is filtered. Method for preventing respiratory diseases includes passive immunisation performed through hypodermic injection of hyperimmune serum containing specific antibodies to rednose, bird flue 3 and bovine viral diarrhea viruses in titres of at least 1:1280, 1:256 and 1:1024 respectively, in dose of 1.5 - 2.0 ml/kg of animal body weight for 15 days with an interval of 12 - 24 hours.

EFFECT: improved efficiency of the agent and prevention method.

2 cl, 2 tbl, 2 ex

FIELD: medicine, veterinary science.

SUBSTANCE: invention concerns veterinary medicine. Treatment-and-preventive agent for young farm animals is alcoholic tincture of vegetable raw material, the raw material being a mixture of grass and blossom cluster of purple Echinacea, coltsfoot, Syrian rue grass and licorice roots. The vegetable raw material is steeped in 70% ethyl alcohol in proportion 1:10, then kept in dark room at a temperature of 15-20°C for 7 days, strained. The raw material is press out and the tincture is filtered. Method for preventing respiratory diseases includes passive immunisation performed through hypodermic injection of hyperimmune serum containing specific antibodies to rednose, bird flue 3 and bovine viral diarrhea viruses in titres of at least 1:1280, 1:256 and 1:1024 respectively, in dose of 1.5 - 2.0 ml/kg of animal body weight for 15 days with an interval of 12 - 24 hours.

EFFECT: improved efficiency of the agent and prevention method.

2 cl, 2 tbl, 2 ex

FIELD: medicine, veterinary science.

SUBSTANCE: invention concerns veterinary medicine. Treatment-and-preventive agent for young farm animals is alcoholic tincture of vegetable raw material, the raw material being a mixture of grass and blossom cluster of purple Echinacea, coltsfoot, Syrian rue grass and licorice roots. The vegetable raw material is steeped in 70% ethyl alcohol in proportion 1:10, then kept in dark room at a temperature of 15-20°C for 7 days, strained. The raw material is press out and the tincture is filtered. Method for preventing respiratory diseases includes passive immunisation performed through hypodermic injection of hyperimmune serum containing specific antibodies to rednose, bird flue 3 and bovine viral diarrhea viruses in titres of at least 1:1280, 1:256 and 1:1024 respectively, in dose of 1.5 - 2.0 ml/kg of animal body weight for 15 days with an interval of 12 - 24 hours.

EFFECT: improved efficiency of the agent and prevention method.

2 cl, 2 tbl, 2 ex

FIELD: medicine, veterinary science.

SUBSTANCE: invention concerns veterinary medicine, namely to agents prepared from medical plants. The invention consists in the following. Mixture of the following medical plants crushed to fine and ultrafine particles and treated with bactericidal lamps rays are placed in a sterile tank of dark glass: dry stalks, leaves and flowers of peppermint, dry flowers of wild chamomile, dry leaves of waybread and dry flower heads of costmary (Tanacetum vulgare), dry stalks, leaves and flowers of yellow melilot, dry grass of St. John's wort, dry flowers of pot marigold, dy grass of milfoil, dy grass of thyme, dry stalks, leaves, flowers and fruits of celandine, dry leaves of eucalyptus, dry leaves and flower heads of coltsfoot, dry leaves of garden sage, dry leaves of stinging nettle, dry grass of common persicaria, dry flowers of densely flowered mullein, bark of ordinary oak, roots of common licoric, ground fruits of anise and rose hips, walnut kernel, buckthorn pulp without kernels, their fruits and berries. These components are treated with bactericidal lamps rays and crushed to fine and ultrafine particles, then placed to a tank of dark glass, mixed with sterile cooking salt solution with 0.9% sodium content, and with formalin. The mixture is left and room temperature for 3-4 days, regularly stirred, and then placed to water bath for 10-12 hours and exposed to temperature up to 40°, with contiuous stirring. After that the liquid part is separated from the vegetable sediment. The tincture is stored in tanks of dark glass or in a darkened room at a temperature of 2-4°C, and is applied externally and internally, and the vegetable sediment is used as fodder and remedy for animals and birds, especially for chickens in case of cannibalism.

EFFECT: at experimental checks of therapeutic efficacy of the agent, good results were achieved in prevention and treatment of inflammatory processes among animals; wide application in veterinary.

3 cl

FIELD: medicine, veterinary science.

SUBSTANCE: invention concerns veterinary medicine, namely to agents prepared from medical plants. The invention consists in the following. Mixture of the following medical plants crushed to fine and ultrafine particles and treated with bactericidal lamps rays are placed in a sterile tank of dark glass: dry stalks, leaves and flowers of peppermint, dry flowers of wild chamomile, dry leaves of waybread and dry flower heads of costmary (Tanacetum vulgare), dry stalks, leaves and flowers of yellow melilot, dry grass of St. John's wort, dry flowers of pot marigold, dy grass of milfoil, dy grass of thyme, dry stalks, leaves, flowers and fruits of celandine, dry leaves of eucalyptus, dry leaves and flower heads of coltsfoot, dry leaves of garden sage, dry leaves of stinging nettle, dry grass of common persicaria, dry flowers of densely flowered mullein, bark of ordinary oak, roots of common licoric, ground fruits of anise and rose hips, walnut kernel, buckthorn pulp without kernels, their fruits and berries. These components are treated with bactericidal lamps rays and crushed to fine and ultrafine particles, then placed to a tank of dark glass, mixed with sterile cooking salt solution with 0.9% sodium content, and with formalin. The mixture is left and room temperature for 3-4 days, regularly stirred, and then placed to water bath for 10-12 hours and exposed to temperature up to 40°, with contiuous stirring. After that the liquid part is separated from the vegetable sediment. The tincture is stored in tanks of dark glass or in a darkened room at a temperature of 2-4°C, and is applied externally and internally, and the vegetable sediment is used as fodder and remedy for animals and birds, especially for chickens in case of cannibalism.

EFFECT: at experimental checks of therapeutic efficacy of the agent, good results were achieved in prevention and treatment of inflammatory processes among animals; wide application in veterinary.

3 cl

FIELD: medicine, veterinary science.

SUBSTANCE: invention concerns veterinary medicine, namely to agents prepared from medical plants. The invention consists in the following. Mixture of the following medical plants crushed to fine and ultrafine particles and treated with bactericidal lamps rays are placed in a sterile tank of dark glass: dry stalks, leaves and flowers of peppermint, dry flowers of wild chamomile, dry leaves of waybread and dry flower heads of costmary (Tanacetum vulgare), dry stalks, leaves and flowers of yellow melilot, dry grass of St. John's wort, dry flowers of pot marigold, dy grass of milfoil, dy grass of thyme, dry stalks, leaves, flowers and fruits of celandine, dry leaves of eucalyptus, dry leaves and flower heads of coltsfoot, dry leaves of garden sage, dry leaves of stinging nettle, dry grass of common persicaria, dry flowers of densely flowered mullein, bark of ordinary oak, roots of common licoric, ground fruits of anise and rose hips, walnut kernel, buckthorn pulp without kernels, their fruits and berries. These components are treated with bactericidal lamps rays and crushed to fine and ultrafine particles, then placed to a tank of dark glass, mixed with sterile cooking salt solution with 0.9% sodium content, and with formalin. The mixture is left and room temperature for 3-4 days, regularly stirred, and then placed to water bath for 10-12 hours and exposed to temperature up to 40°, with contiuous stirring. After that the liquid part is separated from the vegetable sediment. The tincture is stored in tanks of dark glass or in a darkened room at a temperature of 2-4°C, and is applied externally and internally, and the vegetable sediment is used as fodder and remedy for animals and birds, especially for chickens in case of cannibalism.

EFFECT: at experimental checks of therapeutic efficacy of the agent, good results were achieved in prevention and treatment of inflammatory processes among animals; wide application in veterinary.

3 cl

FIELD: medicine, veterinary science.

SUBSTANCE: invention concerns veterinary medicine, namely to agents prepared from medical plants. The invention consists in the following. Mixture of the following medical plants crushed to fine and ultrafine particles and treated with bactericidal lamps rays are placed in a sterile tank of dark glass: dry stalks, leaves and flowers of peppermint, dry flowers of wild chamomile, dry leaves of waybread and dry flower heads of costmary (Tanacetum vulgare), dry stalks, leaves and flowers of yellow melilot, dry grass of St. John's wort, dry flowers of pot marigold, dy grass of milfoil, dy grass of thyme, dry stalks, leaves, flowers and fruits of celandine, dry leaves of eucalyptus, dry leaves and flower heads of coltsfoot, dry leaves of garden sage, dry leaves of stinging nettle, dry grass of common persicaria, dry flowers of densely flowered mullein, bark of ordinary oak, roots of common licoric, ground fruits of anise and rose hips, walnut kernel, buckthorn pulp without kernels, their fruits and berries. These components are treated with bactericidal lamps rays and crushed to fine and ultrafine particles, then placed to a tank of dark glass, mixed with sterile cooking salt solution with 0.9% sodium content, and with formalin. The mixture is left and room temperature for 3-4 days, regularly stirred, and then placed to water bath for 10-12 hours and exposed to temperature up to 40°, with contiuous stirring. After that the liquid part is separated from the vegetable sediment. The tincture is stored in tanks of dark glass or in a darkened room at a temperature of 2-4°C, and is applied externally and internally, and the vegetable sediment is used as fodder and remedy for animals and birds, especially for chickens in case of cannibalism.

EFFECT: at experimental checks of therapeutic efficacy of the agent, good results were achieved in prevention and treatment of inflammatory processes among animals; wide application in veterinary.

3 cl

FIELD: medicine, veterinary science.

SUBSTANCE: invention concerns veterinary medicine, namely to agents prepared from medical plants. The invention consists in the following. Mixture of the following medical plants crushed to fine and ultrafine particles and treated with bactericidal lamps rays are placed in a sterile tank of dark glass: dry stalks, leaves and flowers of peppermint, dry flowers of wild chamomile, dry leaves of waybread and dry flower heads of costmary (Tanacetum vulgare), dry stalks, leaves and flowers of yellow melilot, dry grass of St. John's wort, dry flowers of pot marigold, dy grass of milfoil, dy grass of thyme, dry stalks, leaves, flowers and fruits of celandine, dry leaves of eucalyptus, dry leaves and flower heads of coltsfoot, dry leaves of garden sage, dry leaves of stinging nettle, dry grass of common persicaria, dry flowers of densely flowered mullein, bark of ordinary oak, roots of common licoric, ground fruits of anise and rose hips, walnut kernel, buckthorn pulp without kernels, their fruits and berries. These components are treated with bactericidal lamps rays and crushed to fine and ultrafine particles, then placed to a tank of dark glass, mixed with sterile cooking salt solution with 0.9% sodium content, and with formalin. The mixture is left and room temperature for 3-4 days, regularly stirred, and then placed to water bath for 10-12 hours and exposed to temperature up to 40°, with contiuous stirring. After that the liquid part is separated from the vegetable sediment. The tincture is stored in tanks of dark glass or in a darkened room at a temperature of 2-4°C, and is applied externally and internally, and the vegetable sediment is used as fodder and remedy for animals and birds, especially for chickens in case of cannibalism.

EFFECT: at experimental checks of therapeutic efficacy of the agent, good results were achieved in prevention and treatment of inflammatory processes among animals; wide application in veterinary.

3 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention belongs to food, chemical and pharmaceutical, medical, liquor and biotechnological industries. Previously washed in water and homogenously blended fruits of walnuts with pericarps are subjected to extraction. The prepared raw material is steeped in 35-45% water solution of ethyl alcohol in 1:1 weight ratio. The mixture is infused for 6-7 days away from light, then extracted with ultrasound in cavitation mode for 30-60 min at a temperature of 15-18°C; after that extraction is repeated at least 5-6 times, each subsequent extaction being carried out after the mixture has been infused for 3-4 days max. Eventually, the extract is separated by filtration and cooled.

EFFECT: increased content of biologically active substances in a supplement.

3 cl

Up!